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I. SUMMARY  
 
Infectious diseases, particularly in less developed countries, remain among the leading causes 
of global mortality, most of these infections are caused by Gram-negative bacteria which are 
the major pathogens responsible of neonatal sepsis and cause of a range of diarrheal, 
respiratory and invasive diseases. 
The most frequent gram-negative isolates are E.coli, Salmonella spp and Shigella spp. 
Salmonella infection represents a considerable burden in both developing and developed 
countries. Efforts to reduce transmission of salmonellae by food and other routes must be 
implemented on a global scale thus the development of cost effective, needle-independent 
vaccines is a high priority.  
Vaccine for Developing Countries should be designed to be inexpensive (less than one euro 
for association like UNICEF and GAVI), stable at room temperature, simple to administer to 
infants, readily administered by nonprofessionals using a needle-free method and the vaccines 
formulation would protect against multiple agents. 
Novartis Vaccines Institute for Global Health (NVGH) aims to develop a broadly protective 
vaccine using outer membrane particles. These particles, called Generalized Modules for 
Membrane Antigens (GMMA), also known as outer membrane vesicles (OMV), are naturally 
shed from the surface of living Gram‐negative bacteria. GMMA are different from the 
detergent‐extracted OMV which are depleted of lipooligosaccharides and lipoproteins. 
The purpose of this PhD project was to investigate the possibility to develop low cost vaccines 
applicable to Gram-negative strains, intended for neglected infectious diseases of 
impoverished communities, using the GMMA technology platform.  
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This work showed the possibility to use GMMA particles as starting material for membrane 
components extraction, optimizing new and innovative platform, particularly for LPS or 
proteins recovery, in order to decrease the costs of goods (COGs). 
The present work is focused on the O: 4,5-antigen polysaccharide extraction (using the acid 
hydrolysis approach), purification and characterization from Salmonella Typhimurium 
SL1344 tolR
-
  GMMA.  
NVGH, to over produce and collect GMMA, is developing new methods using over producing 
GMMA mutant strain (the tolR gene deletion results in substantial overproduction of outer 
membrane blebs) and two consecutive TFF steps (Tangential Flow Filtration steps: micro-
filtration at 0.2 µm and thereafter a second micro-filtration at 0.1 µm) at the end of the 
fermentation process to collect GMMA from bacterial suspensions. 
NVGH has developed another innovative platform for O-antigen extraction from biomass at 
the end of the fermentation process, using the acid hydrolysis approach of whole bacterial 
culture.  
The present work shows for the first time the possibility to use GMMA particles as O-antigens 
source (and in general as source of membrane components) due their membrane composition 
enriched in LPS. We have proven that, O-antigens can be extracted from GMMA using the 
direct acid hydrolysis method thus the consequent O-antigen purification process is easy and 
cost effective. 
This work provides the basis for the development of new vaccines, glyconiugate or proteins 
based, exploiting the same approach used and developed for S. Tyhphimurium SL1344 tolR
-
 
GMMA, which could be applied to other Gram negative strains.  
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II. INTRODUCTION 
 
1. ENTERIC DISEASES IN DEVELOPING COUNTRIES 
 
Every year 3·3 million babies die within the first 28 days of life (the newborn or neonatal 
period); newborn deaths account for 41% of all child deaths in developing countries. Another 
million babies are stillborn. Effective interventions could prevent most of these deaths. The 
challenge is to identify strategies that can be implemented feasibly in the short term to ensure 
that newborn babies have access to these life-saving interventions [1,2]. 
Infectious diseases, particularly in less developed countries, remain among the leading causes 
of global mortality, exceeding 60% in children up to 4 years old [3]. 
Poor sanitary conditions, unsatisfactory traditional practices concerning waste disposal and 
poor personal hygiene in general, facilitate the spread of enteric pathogens [4]. 
Only washing hands with soap could be possible reduce the risk of diarrheal diseases by 42–
47% and interventions to promote hand-washing might save a million lives [5], but no radical 
improvements of these conditions can be expected in most developing countries in the near 
future. Thus, vaccines become very important in the multi-faceted approach necessary to 
control diarrheal diseases either through protection or treatment [6].  
In addition to the acute morbidity and mortality associated with enteric diseases, diarrhea is a 
cause and effect of malnutrition, which may be one of the greatest yet of the “emerging 
infectious diseases” (Bill and Melinda Gates Foundation, Enteric and Diarrheal Diseases, 
strategy overview) [7]. 
The consequences of early childhood diarrhea on growth and also on physical and cognitive 
development lead to tremendous losses of human potential and productivity [8]. 
Enteric diseases are also a significant cause of morbidity among people from more developed 
countries. In the United States, for example, diarrhea is one of the most frequent reasons given 
for visits to the pediatrician’s office and it is also a major threat to travelers [9].  
Malnutrition remains the major adverse prognostic indicator for diarrhea related mortality [10]. 
The wide diversity of bacterial and viral infections that may cause diarrhea [11] complicates 
accurate surveillance and diagnosis especially in developing countries with little or no access 
to modern laboratory procedures. The specific disease burden attributable to particular 
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infectious antigens is particularly complex, given the multiplicity of these antigens and their 
serotypes, and its accurate documentation depends largely on laboratory facilities.  
Gram-negative are major pathogens of neonatal sepsis in developing countries, these bacteria 
causing a range of diarrheal, respiratory and invasive diseases [12]. 
The most frequent gram-negative isolates are E.coli, Salmonella spp and Shigella spp, these 
include pathogens that are non-invasive, such as Vibrio cholerae and enterotoxigenic 
Escherichia coli (ETEC); pathogens that produce gut inflammation, such as Shigella and 
rotavirus; and pathogens that invade through the intestine and enter the systemic circulation, 
such as Salmonella typhi, polio virus, and human immunodeficiency virus [13].   
Preventive strategies on a global scale might ultimately hold the greatest potential to reduce 
the burden of diarrhoeal disease. These strategies include vaccines and, most importantly, 
policies to address persisting inequalities between the developed and developing countries 
[10]. While, in the long term, access to clean water, better hygiene, adequate nutrition, and 
improvement of sanitary measures would certainly have the greatest impact on diarrheal 
diseases [12]. 
 
2. CURRENT STATUS OF VACCINES DEVELOPMENT 
 
Infectious diseases remain a major cause of deaths and disabilities in the world, the majority of 
which are caused by bacteria. Although immunization is the most cost effective and efficient 
means to control microbial diseases, vaccines are not yet available to prevent many major 
bacterial infections. Examples include dysentery (shigellosis), gonorrhoea, trachoma, gastric 
ulcers and cancer by Helicobacter pylori. Improved vaccines are needed to combat some 
diseases for which current vaccines are inadequate [14] thus the modern biotechnology is 
allowing the development of new vaccines against diseases that were previously unassailable 
[15]. 
Enteric infections resulting in diarrheal disease remain a leading global health problem. Acute 
diarrheal disease may be caused by several infectious agents and the relative contribution of 
any specific agent requires laboratory identification of the agent from patients [16] [14,17]. 
The establishment of the germ theory and the identification of specific microbes as the 
causative agent of a wide variety of infectious diseases led to enormous progress, notably the 
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development of vaccines and ultimately of antimicrobials. Research efforts focus on the 
development of vaccines and new drugs, and on re-establishing public health measures [18].  
93.8 million Cases of gastroenteritis due to Salmonella species occur globally each year, with 
155,000 deaths. Salmonella infection represents a considerable burden in both developing and 
developed countries. Efforts to reduce transmission of salmonellae by food and other routes 
must be implemented on a global scale [19] thus  the development of cost effective, needle-
independent vaccines is a high priority [20].  
The history of vaccine development can be marked by a number of milestones resulting from 
revolutions in technology. Earlier waves involved pathogen attenuation, inactivation, and viral 
cell 
culture, all supported by an increased understanding of the human immune response [21]. 
However, recombinant DNA technology has probably been the single most innovative 
advance that has opened the door to new technological developments. 
 
A. New vaccines technological development 
 
a) Recombinant DNA Technology 
 
Recombinant DNA technology was first successfully applied to vaccines over 25 years ago, 
with the production of a recombinant vaccine for Hepatitis B virus (HBV) [22]. Along with the 
need for developing better-characterized , less reactogenic or more potent vaccines to replace 
the existing vaccines, a more recent driver for developing recombinant subunit proteins has 
been the need to provide broader protection against multiple strains or serotypes of a 
bacterium (e.g., serogroup B meningococcus, pneumococcus).  
Strategies to increase the breadth of vaccine coverage include the engineering of multiple 
epitope based vaccines, incorporating epitopes either from different antigens of the same 
pathogen or even from different pathogens into a single protein using synthesized genes [22]. 
Another major use of recombinant DNA technology has been in site-specific inactivation of 
toxins as a safe and efficient alternative to chemical inactivation. The use of recombinant 
DNA has been applied to the genetic attenuation of bacteria and viruses for use in live 
attenuated vaccines. Previously, attenuation of bacteria or viruses was achieved through serial 
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in vitro passage or random chemical mutagenesis, with the potential accumulation of unknown 
and uncharacterized mutations and the risk of reversion. By contrast, recombinant, attenuated 
vaccines are specifically engineered to inactivate defined target functions with non-reverting 
mutations. 
The rational design behind genetically engineering a recombinant vaccine strain should find 
the right balance between attenuation and immunogenicity.  
One of the most commonly used mutations for generating vaccines for intracellular pathogens 
such as Samonella and Shigella are aro gene mutations, which disable the shikimate pathway 
essential for the biosynthesis of aromatics including the aromatic amino acids [23].  
Currently, candidate live vaccine strains are being constructed that combine different 
mutations, which optimize the balance between attenuation, reactogenicity and 
immunogenicity, highlighting the need to understand the organisms’ physiology and 
interaction with the host as well as protective immune responses to the disease [24–26]. 
 
b) Conjugate Vaccines 
 
The use of protein-conjugated polysaccharides as a tool for the prevention of diseases caused 
by encapsulated bacteria has proved to be highly successful in the development of effective 
vaccines against Haemophilus influenzae, Neisseria meningitidis, and Streptococcus 
pneumoniae.  
Subunit vaccines based on purified capsular polysaccharide can elicit protective immune 
responses in adults and are the basis of licensed multivalent pneumococcal and meningococcal 
polysaccharide vaccines. However, these have not been widely exploited as they were shown 
to result in short-lived protective immunity and to be ineffective in infants, largely because of 
their inability to engage a T cell–based immune response. The development of conjugate 
vaccines derived from polysaccharides of the capsule chemically conjugated to tetanus toxoid 
or diphtheria CRM197 carrier proteins resulted in a T-dependent antigen capable of protecting 
young children and providing long-term immunological memory [27].  
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c) Reverse Vaccinology 
 
Genome mining has revolutionized the approach to vaccine development and provided a new 
innovation to antigen selection and design. The approach starting from the genomic 
information leading to the identification of potential vaccine candidates is termed ‘‘reverse 
vaccinology’’ [28]. The availability of complete bacterial genome sequences offers a 
comprehensive catalog of genes encoding all the potential protein antigens of a pathogen, with 
the possibility of rational selection of vaccine candidates rather than empirical testing of 
antigens, one at a time. Furthermore, the prediction of antigens is independent of the need to 
culture the pathogen in vitro, to establish the abundance of the antigen, and to understand 
which antigens will be expressed in vivo. On the basis of the concept that surface-exposed 
antigens are susceptible to antibody recognition and are therefore the most suitable vaccine 
candidates, a complete genome can be screened using bioinformatic algorithms to select open 
reading frames (ORFs) encoding putative surface-exposed or secreted proteins. 
Surface proteins are readily identified in genomic data based on the combination of several 
pieces of information, including the presence of amino acid motifs that are responsible for 
targeting the mature protein to the outer membrane (signal peptides), to the lipid bilayer 
(lipoproteins), to the integral membrane (hydrophobic transmembrane domains), or by 
searching for motifs indicative of surface location such as sortase attachment sites (otherwise 
known as LPXTG sites) or motifs for recognition and interaction with host proteins or 
structures (e.g., adhesins having integrin-binding domains). 
Furthermore, screening for sequences homologous to those of human proteins for their 
exclusion in the selection process can help to avoid problems of autoimmunity. Currently 
available software and bioinformatic techniques for antigen discovery have been recently 
reviewed [29].Furthermore, current efforts are aimed at refining algorithms to enable 
biotechnologists to follow ‘‘computer-aided strategies’’ based on experiments driven by high-
confidence predictions. Some groups are currently involved in developing and tuning 
integrative approaches and user-friendly, automated bioinformatics environments [30]. For 
example, NERVE (New Enhanced Reverse Vaccinology Environment) represents a user-
friendly software environment, which attempts to bring together a similar body of principles 
into an automated pipeline resembling a reverse vaccinology process. 
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After candidate surface antigens are identified in silico, they are produced in vitro and their 
immunogenicity is assayed to measure their relative power as potential vaccine candidates. 
The first application of this genomic approach led to the identification of novel vaccine 
candidates against N. meningitides serogroup B (MenB) [31,32]. 
 
B. Vaccine Prices and Costs 
 
Developing country access to vaccines has been critically dependent on differential pricing 
(also called tiered pricing, equity pricing, and price discrimination), whereby different prices 
are charged for the same products in different markets. 
Under differential pricing, manufacturers charge a much lower price in the poorest developing 
country markets, allowing these countries access to the product, and charge much higher 
prices in the industrialized markets, allowing the manufacturer to recoup its research and 
development expenditures and overheads. 
In the 1990s, financing of vaccines for low-income country markets also began changing. The 
global immunization community formed the GAVI Alliance, and large amounts of funding for 
the purchase of vaccines for the world’s poorest countries were funneled through this public-
private partnership. 
The costs associated with product development are incurred in four distinct stages:  preclinical 
research, identifying a promising vaccine candidate through early clinical studies in humans, 
developing and testing a candidate for a target market, and scaling up manufacturing capacity 
for that market [33–35]. 
Assuring a vaccine for global use requires two additional stages of investment: relevance, 
adapting and testing a vaccine to ensure safety and efficacy in additional populations, and 
supply, ensuring adequate manufacturing capacity and funding/pricing structures to enable 
broad developing country access. If a new vaccine is to be broadly available at the earliest 
possible technical and regulatory opportunity, a manufacturer must make development and 
capital investments explicitly to support supply to the developing world markets. 
For there to be a business case for such incremental investments, a return must be available 
either directly from the developing world market or through other special financing 
interventions. In the case of vaccines for which no significant industrial market exists, such as 
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malaria, it follows that the developing country market and associated financing must fund, and 
provide a return on, the entire investment [35]. 
Vaccine production has two main stages, bulk production consisting of activities such as 
growing or producing by fermentation the active ingredients, and purifying the result, and 
fill/finish consisting of activities such as blending, filling vials, lyophilizing where applicable, 
labeling, and packaging. All suppliers require production facilities with appropriate quality 
control and quality assurance that are in compliance with current Good Manufacturing 
Practice (cGMP), as required by the regulatory authorities. The costs associated with vaccine 
production can be categorized as variable (unit cost is constant for each vial), semi-variable or 
batch fixed (costs associated with each batch), and fixed (costs are independent of volume or 
number of batches and are fixed at the site or company level). Vaccine production is largely a 
‘‘fixed cost business,’’ in that the majority of costs are fixed at either the batch or site level 
(plant, equipment, animals, labor), leaving only a relatively small percentage truly variable 
(vials, stoppers, raw materials).  
In general, the fixed cost nature of vaccine economics means that unit costs fall rapidly with 
increases in volume. Timing becomes particularly important because the capacity and batch 
size for a given vaccine are largely determined at scale-up, and are thereafter expensive and 
time consuming to increase. The cost to produce vaccine varies significantly from product to 
product (Tremonti G. Advance Market Commitments for New Vaccines: A Tool in the Fight 
Against Disease and Poverty. Report to the G8 Finance Ministers, London, U.K. Advanced 
Market Commitments for Vaccines; 2005). 
Three types of analyses are commonly used to assess the economic rationale for immunization 
or other health-related programs: cost-benefit (CB), cost-effectiveness, and cost-utility 
analyses. 
Cost-benefit analyses (CBAs) compare the monetary benefits from implementation of a health 
program with its monetary costs. All values in a CBA, including health outcomes, are 
converted to monetary units, resulting in an outcome that is expressed as money saved or 
spent.  
The Cost-effectiveness analysis (CEA) assesses the value of a program by calculating the 
expenditure per health outcome achieved (net cost/net health effect). Common outcomes 
include cost per case prevented and cost per death averted. 
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Cost-utility analysis (CUA) is a subset of CEA. In CUA, as with CEA, outcomes are 
expressed as cost per change in health status; thus, health outcomes do not need to be 
converted into monetary equivalents. However, a common metric is established that allows 
comparison of qualitatively different health outcomes. [36,37] [38]. 
Cost of Goods Sold, also known as COGS, is one of the most difficult, yet important elements 
of business to understand.  The basic definition of cost of goods sold is: the direct costs 
attributable to the production of the goods sold by a company. This amount includes the cost 
of the materials used in creating the good along with the direct labor costs used to produce the 
good. 
One of the main drivers for continuous process improvement is COGS reduction. 
Manufacturing costs do not in general directly determine vaccine prices, which are set by 
profit-seeking firms in markets that are more or less competitive. But they do set a floor below 
which prices cannot fall even in tiered pricing or highly competitive situations. Vaccine 
production costs include variable costs associated with each dose of vaccine (“cost of goods”), 
which include the cost of the vaccine components, vials, and so on; “semi-fixed” costs 
associated with each production batch, including quality tests; and the fixed costs of plant and 
equipment. Fixed and semi-fixed costs make up the bulk of total cost, typically contributing 60% 
and 25% respectively; this gives vaccine manufacture large economies of scale, since average 
costs fall with increasing volume over a large range [39]. 
The main factors that determine manufacturing cost are vaccine and production technology, 
presentation, and manufacturing scale. Location of production matters, as some costs are 
lower in developing countries. 
Vaccines of different types can have dramatically different costs of production. At one end of 
the spectrum, simple live-attenuated vaccines such as oral polio or measles can be produced in 
very large batches from very inexpensive inputs, and cost no more than a few pennies per dose. 
At the other extreme, the new pneumococcal conjugate vaccines require the manufacture or 
purchase of purified bacterial polysaccharides, conjugation of these polysaccharides to a 
protein carrier, mixing and carefully balancing of component vaccines against as many as 13 
bacterial strains or serotypes, and a very large number of quality control steps. These vaccines 
cost $1-3 per dose to produce not counting the cost of the plant itself. Production technology 
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also determines batch size, which is itself an important determinant of cost, since some 
expenses are incurred on a per-batch basis [40,41]. 
The cost of producing technologically sophisticated vaccines can be expected to come down 
over time as firms accumulate experience and as more efficient production technologies are 
developed. But the nature of some vaccines makes them intrinsically more costly to 
manufacture than others. For this reason, choices made during the earliest stages of vaccine 
development have critical consequences for later manufacturing cost. Once a technology has 
been chosen, producers are largely locked in.  
Design choices are also critical, and market incentives in rich countries may drive the 
development of more complex, and thus expensive, vaccines than are required for public 
health impact. 
Several new vaccines with vital implications for developing countries have come to market 
recently, every effort must be undertaken to ensure that children in these countries gain access 
to them. This will depend both on raising additional funds and bringing prices for newer 
vaccines down by accelerating the entry of emerging suppliers into these markets. Technology 
and know-how transfer will be crucial, and will also help emerging suppliers to assume a 
larger role in vaccine research and diagnostic (R&D). And innovative models to stimulate 
R&D will be critical to meeting still-unaddressed vaccine needs [42]. 
Vaccine for Developing Countries should be designed to be inexpensive (less than one euro 
for association like UNICEF and GAVI), stable at room temperature, simple to administer to 
infants, readily administered by nonprofessionals using a needle-free method and the vaccines 
formulation would protect against multiple agents [43]. 
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a) The Meningitis Vaccine Project (MVP) 
 
The Meningitis Vaccine Project (MVP) is an intriguing model of vaccine development for 
developing countries, in which a vaccine with specific characteristics tailored to a particular 
population is developed at a modest cost and provisions to ensure sustainable access are built 
in from the start. Although similar to the larger vaccine Product Development Partnership 
(PDPs), its approach has differed in several ways. The MVP was established in 2001 by  
PATH and WHO to develop an effective and affordable vaccine to combat the epidemics of 
bacterial meningitis, causedmostly by group A strains of Neisseria meningitidis 
(“meningococcus”), which plague the so-called “meningitis belt” in sub-Saharan Africa 
(www.who.int). While polysaccharide vaccines have been available for many years, they have 
limited duration of protection and are not effective in very young children (WHO. 
Immunization, Vaccines and Biologicals. www.who.int). So-called “conjugate” vaccines, like 
the one produced by Sanofi, in theory overcome these disadvantages. But the Sanofi conjugate 
vaccine, an ACYW-strain tetravalent, is more expensive to produce (four conjugate vaccines 
instead of just one). Even at a heavily discounted price, it would likely remain far more 
expensive than a monovalent vaccine. 
After identifying and licensing an appropriate conjugation technology from the U.S. FDA 
(U.S. Food and Drug Administration) and negotiating with several possible industrial partners, 
the MVP reached agreement with Serum Institute of India (SIIL) to produce the new 
monovalent meningitis A conjugate vaccine at an affordable price for the African market. In 
exchange for price and supply commitments, SIIL benefited from transfer of technology and 
know-how. PATH funded the clinical trials. 
Significant progress has been made. In December 2009 market authorization for the Men A 
conjugate vaccine was granted by the Drugs Controller General of India and the WHO 
prequalification process has begun. Plans are being made for introduction at public health 
scale in Burkina Faso in late 2010. The total research and development costs for this vaccine 
are estimated to be about $60 million, not including the cost of the manufacturing plant; SIIL 
has committed about $15 million to the project. 
The MVP’s approach differs in some respects from that of the larger PDPs: 
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• Focus on low cost: Consultations at the start of the project established that to ensure long-
term access a vaccine should cost no more than $0.50/dose. MVP emphasized this requirement 
in discussions with vaccine manufacturers.  
• Focus on a single candidate and single supplier: Unlike most product development 
partnerships that maintain a portfolio of vaccine candidates, MVP focused on a single 
candidate and on SIIL as the sole supplier. The relatively high probability of success in 
making a monovalent conjugate vaccine lowered the risk when compared to a malaria or 
Tuberculosis (TB) vaccine, where the risks of R&D failure are high. 
• Partnership with an emerging supplier: The choice of an emerging supplier was critical to 
achieving the goal of low cost, in part because the access to technology and visibility 
associated with the project made the partnership more attractive to SIIL than to a multinational 
firm. In addition, producing for a high-volume, low-margin developing country market was 
consistent with SIIL’s established business model. 
• Public sector technology transfer: The transfer of a non-exclusive license for an efficient 
conjugation technology through the NIH (U.S. National Institutes of Health) Office of 
Technology Transfer, coupled with active transfer of know-how, was central to the success of 
the project.  
 
To a great extent, these choices were made possible because several meningococcal conjugate 
vaccines had already been developed, the technologies were well understood, and correlates of 
protection for Meningitis A were known. These data made focusing on one candidate a 
reasonable bet, allowed emerging suppliers to be considered as manufacturing partners, and 
kept costs relatively low. The MVP model is therefore particularly suited to the development 
of adapted versions of vaccines based on established technologies, such as for rotavirus, 
pneumococcal or HPV vaccines. On the other hand, the development of AIDS, TB and 
malaria vaccines is far more challenging and probably requires different models. 
Other forms of push funding for vaccine development are under discussion, including new 
funds that would pool donor resources and allocate them among PDPs and possibly firms, 
proposals to use bond markets to raise long-term funding for PDPs, as well as currency 
transaction levies or financial transaction taxes. 
16 
 
An alternative to the PDP model of publicly subsidized collaboration with the private sector 
would be to rebuild capacity in the public sector to develop and test vaccines. 
(Special Report: Giving Developing Countries the Best Shot: An Overview of Vaccine Access 
and R&D, May, 2010) 
 
C. Reaching Every Child: Achieving Equity in Global Immunization 
 
In the year 2000, ambitious millennium development goals were underwritten by all nations. 
These goals include a two-thirds reduction in child mortality by 2015. For this to be achieved, 
the full potential of the global EPI network must be exploited to prevent the 1.4 million 
vaccine-preventable childhood deaths that continue to occur every year. Preventing these 
deaths requires extending the reach of immunization services to the more than 25% of the 
world’s children who are yet to have regular access to immunization, the most cost-effective 
of health interventions. Particular attention must be given to increasing coverage among the 
world’s poorest children who are disproportionately affected by vaccine-preventable and 
infectious diseases. That reaching all children with immunization is a feasible goal is 
abundantly evident in the progress achieved and experience gained over the past 25 years. 
With the increased attention and funding for immunization, mainly through the Global 
Alliance for Vaccines and Immunization (GAVI) and a realization that immunization, both 
current and future vaccines, would play a major role in reaching the millennium development 
goals for child survival, WHO and UNICEF in 2004/2005 developed a strategic document, the 
Global Immunization Vision and Strategy (GIVS), which outlined the overall vision, direction, 
and core strategies.  
GIVS set new global goals in immunization for routine vaccination, it requires that all 
countries should reach 90% of their children with vaccines, and in terms of measles control, it 
dictates that mortality should be reduced by 90% compared to the 2000 level. The document 
describes four key strategic areas that would allow immunization programs to grow further. 
The first strategic area ‘‘protecting more people in a changing world’’ outlines strategies to 
expand the reach of vaccinations both geographically (by targeting the hard-to reach) 
populations and in terms of age groups, requiring the expansion of vaccination programs to 
reach children beyond the first year of life. The second strategic area ‘‘introducing new 
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vaccines and technologies’’ describes the strategies needed to support countries to make the 
decision, and to implement new vaccine or technology introduction. In the third strategic area 
‘‘integrating immunization, other linked health interventions, and surveillance in the health 
systems context,’’ the need for immunization programs to work in coordinated and integrated 
fashion with other programs, and the basic health system itself is outlined. This area also 
contains the key strategies required to broaden and strengthen the surveillance and monitoring 
systems necessary to run a successful public health program. 
Finally, in recognition that the immunization program operates in a global context of 
interdependency, the fourth strategic area ‘‘immunizing in the context of global 
interdependence’’ describes the necessity of sustainable financing and supply of vaccines of 
assured quality, as well as communication, information dissemination, partnerships, and global 
epidemic preparedness. 
UNICEF and WHO have substantially enhanced long-term vaccine demand forecasting 
capacity, improved their knowledge of the vaccine market, increased dialogue with 
manufacturers, explored arrangements for longer-term funding and contracts for vaccines, and 
promoted sustainable financing mechanisms. 
The challenge will be to exploit the opportunities that exist to establish true equity in global 
childhood immunization. 
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3. SALMONELLA: a general overview 
 
Salmonella infections in humans are divided into typhoid fever caused by S typhi and S 
paratyphi and a range of diarrhoeal diseases caused by a large number of non-typhoidal 
Salmonella serovars (NTS). These NTS, which usually have a broad vertebrate host range, 
show dramatically more severe and invasive presentation in immunocompromized individuals 
[44]. 
Typhoid fever (TF) is a more classical systemic infection caused by the typhoid bacillus, 
Salmonella enteritica serovar Typhi (commonly referred to as S. typhi), the most common 
cause of enteric fever, which also includes paratyphoid fever caused by S. paratyphi A, B and 
C. These pathogens only infect humans. The disease is transmitted by ingestion of food, 
including dairy products, or water contaminated by excreta from patients or chronic carriers or 
handled by infected persons  [45]. 
 
A. Bacteriology 
 
The most recent classification, based on DNA sequences, has left only two species, S. 
enteritica and S. bongori, further subdivided into subspecies and serovars. To avoid confusion, 
S. enteritica serovar Typhi continues to be referred to as S. typhi [46]. 
According to this system of nomenclature, “Salmonella typhimurium” would be renamed 
“Salmonella enterica serotype Typhimurium.” Although this proposal was not formally 
adopted by the International Committee of Systematic Bacteriology, these names have become 
accepted for use by the World Health Organization and in publications of the American 
Society for Microbiology. Most medical laboratories continue to report clinically familiar 
names, such as Salmonella typhimurium or Salmonella serotype Typhimurium. Although 
Salmonella typhi, the most frequent causative antigenent of enteric fever, may be rapidly 
identified (serogroup D; Vi-antigen positive) by use of commercial agglutination tests in all 
laboratories, Salmonella paratyphi and the multitude of nontyphoidal salmonellae are, variably, 
members of serogroups B and D and, less frequently, of serogroups A and C. Final serotyping 
will often require a reference laboratory and not be immediately available. Fortunately, 
clinical decision-making is based primarily on the host, severity of illness, and antimicrobial 
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susceptibilities, and not specific serotype. Identification of Salmonella species in the 
bacteriology laboratory is not difficult. The best recovery of such species from fecal samples 
can be achieved by the use of direct plating and inoculation of standard enrichment broths 
[47,48].  
Upon ingestion, typhoid bacilli rapidly penetrate the small intestinal mucosa by transcytosis 
through M cells and enterocytes, and are taken up by macrophage or diffuse into mesenteric 
lymph nodes. A primary bacteremia follows and the pathogen rapidly attains intracellular 
haven throughout the reticuloendothelial system. This is followed by a sustained secondary 
bacteremia associated with clinical illness. S. typhi also shows remarkable predilection for the 
gall-bladder where infection tends to become chronic, especially in individuals with a 
pathologic gall-bladder condition [49] . 
 
B. Disease Burden 
 
a) TYPHOID FEVER 
 
Typhoid Fever (TF) is spread by the fecal-oral route and closely associated with poor hygiene, 
lack of clean drinking water and inadequate sanitation. The disease is almost exclusively 
transmitted by food and water contaminated by the faeces and urine of patients and carriers. 
Polluted water is the most common source of typhoid transmission. In addition, shellfish taken 
from sewage-contaminated beds, vegetables fertilized with night-soil and eaten raw, 
contaminated milk and milk products have been shown to be a source of infection. Although 
TF has practically disappeared from industrialized countries, it remains a serious public health 
problem in several Asian regions of the former USSR and in parts of South and South-East 
Asia, Africa and South America. In the last outbreak in the Democratic Republic of Congo, 
between 27 September 2004 and early January 2005, no less than 42 564 cases of typhoid 
fever were reported, including 214 deaths and 696 cases of peritonitis and intestinal 
perforations. Also, multiresistant strains of S typhi are becoming increasingly common 
worldwide, further compounding the risk to people living in regions with high endemic 
disease and to travelers [50,51] [52].  
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Strains resistant to chloramphenicol and other recommended antibiotics (ampicillin, 
cotrimoxazole and even ciprofloxacin) have become prevalent in several areas of the world 
[53]. 
TF is characterized by the sudden onset of sustained fever, severe headache, nausea, 
abdominal pains, and loss of appetite, constipation or sometimes diarrhea. The illness can last 
for several weeks and even months. The most frequent complications, which arise with a 
frequency of 1% to 4%, include gastro-intestinal bleeding and intestinal perforation [54]. 
Severe neurological forms also have been described with mental dullness, stupor, delirium and 
shock. Hospitalization of TF cases varies from 10% to 40% of cases and usually lasts for 10-
15 days or more. Case-fatality rates, which varied from 10% to 30% before the advent of 
antibiotics, has now been reduced to about 1%-4% with appropriate antibiotic therapy [54]. 
Paratyphoid fever, which is caused by any of three serotypes of S. paratyphi A, B and C, is 
similar in its symptoms to typhoid fever, but tends to be milder, with a lower fatality rate [55]. 
People can transmit TF as long as the bacteria remain in their body; most people are infectious 
prior to and during the first week of convalescence, but 10% of untreated patients will 
discharge bacteria for up to 3 months. In addition, 2–5% of untreated patients will become 
permanent, lifelong carriers of the bacteria in their gall-bladder. 
The true burden of TF in developing countries is difficult to estimate. According to recent 
estimates, 22 million (range 16 million - 33 million) cases occur each year causing 216,000 
deaths, predominantly in school-age children and young adults. Asia, with 274 cases per 
100,000 persons has the highest incidence of TF cases worldwide, especially in Southeast 
Asian countries and on the Indian subcontinent, followed by sub-Saharan Africa and Latin 
America with 50 cases per 100,000 persons. In an urban slum in Dhaka, incidence of 
bacteremia TF was found to be 390/100,000 population, with a 9-fold higher risk for pre-
school children than for older persons [56]. 
Recent prospective population-based disease-surveillance studies supported by the Bill and 
Melinda Gates Foundation and conducted by the Diseases of the Most Impoverished (DOMI) 
Program at five sites in China, India, Indonesia, Pakistan and Vietnam revealed high rates of 
TF among children in urban slums, including children below 5 years of age. In three urban 
slums in Karachi, Kolkata and North Jakarta, incidence of blood-confirmed TF cases among 
children 5 to 15 years of age ranged from 180 cases to 494 cases per 100,000  [57,58]. 
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The introduction of TF vaccines in routine vaccination programs in Asia would be highly 
beneficial in view of the burden of disease and cost of illness to governments and individuals 
[59]. But, so far, only two countries, China and Vietnam, have incorporated typhoid 
vaccination into their routine immunization programs, and only in a limited fashion. The Delhi 
State, India, also introduced vaccination in 2004 in 2-5 years old children through community-
based campaigns. The reason why these efforts have not be more generalized lies in part in the 
fact that most developing countries are uncertain of their true TF disease burden, due to lack 
of rapid diagnostic tools, infrequency of laboratory testing and poor reporting system (Report 
of the Meeting on Typhoid Fever, a Neglected Disease: Towards a Vaccine Introduction 
Policy ). Most cases of TF in industrialized countries are imported cases from endemic 
countries [60]. 
 
b) NON-TYPHOID SALMONELLAE 
 
Non-typhoid salmonellae are among the primary causes of food-borne gastroenteritis. Most 
infections result in self-limiting diarrhea and do not require antimicrobial treatment. However, 
invasion of the bloodstream and life-threatening metastatic infections, such as meningitis, are 
more common in infants, the elderly and immune-compromised patients [61]. 
Annually, approximately 40 000 cases of non-typhoid salmonellosis are reported to the 
Centers for Disease Control and Prevention (CDC). These numbers underestimate the 
magnitude of the problem, as many cases of salmonellosis are not reported because the ill 
person either does not visit a physician, no specimen is obtained for laboratory tests or the 
laboratory findings are not communicated to the CDC. Taking into account the degree of 
under-reporting, the CDC estimates the annual number of non-typhoidal salmonellosis cases in 
the US to be approximately 1.4 million [62,63]. Furthermore, with an estimated 582 annual 
deaths resulting from non-typhoid salmonellosis this pathogen is the leading cause of 
foodborne infections with lethal outcome in the US. The most common vehicles of 
transmission are meat, meat products, eggs and egg products that contain Salmonella serovars 
because animals are infected or because fecal contamination occurs during processing [64]. 
The majority of human cases are caused by only a few non-typhoid serovars. For instance, 
approximately 60% of human cases reported to the CDC in 1995 were caused by four serovars, 
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including Salmonella enteritidis (24.7%), S. enterica serovar Typhimurium (23.5%), S. 
newport (6.2%) and S. heidelberg (5.1%)  [CDC, Salmonella surveillance: annual tabulation 
summary1993–1995 US Department of Health and Human Services, CDC, Atlanta, 1996]. 
These four serovars also represented 46.4% of strains isolated from non-human sources that 
year. The dominance of only a few serovars is even more pronounced in Germany, where S. 
enteritidis (61.3%) and S. Typhimurium (23.4%) accounted for more than 80% of human 
isolates reported to the enteric reference center at the Robert Koch Institute in 1995. 
The epidemiological surveys by the Central Veterinary Laboratory revealed a steady increase 
in multi-drug resistant S. Typhimurium isolates in England and Wales. The percentage of S. 
Typhimurium isolates resistant to multiple antibiotics increased from 5% in 1981 to 19% in 
1990 [65].  Multiple resistance has continued to increase, resulting in 81% of S. Typhimurium 
isolates from England and Wales being multi-resistant in 1996 [65].  
However, antimicrobial resistance, sometimes more prevalent than in S. typhi, is clinically 
relevant because 3–10% of these infections can progress to life-threatening bacteraemia, 
particularly in young children and HIV-infected people [66]. In Indonesia, Tjaniadi although S. 
typhi and S. paratyphi isolates recovered between 1995 and 2001 were universally susceptible 
to commonly used antimicrobials, Salmonella enteritidis isolates were resistant to most of the 
antimicrobials tested, with the exception of the fluoroquinolones [67]. Similarly, Zimbabwean 
study reported much lower rates of resistance among .S enteritidis [68,69], more than 50% of 
non-typhoidal salmonella isolates from children in Kilifi, Kenya, were multidrug resistant 
[69,70]. The potential consequences of these pockets of multidrug-resistant salmonella could 
be increased health costs even if infection rates are not increased. In a controlled study, Martin 
and co-workers found that patients infected with multidrug-resistant S. enterica serovar 
Typhimurium were more likely to be hospitalised than those infected with susceptible strains 
[70].  
Available data suggest that resistance has reached unacceptable levels in the pathogens most 
common in developing countries and that trends show further increases. Resistance appears to 
have emerged and spread rapidly in many areas, with important consequences for individual 
patients and public health. The agents most affected are inexpensive, older antimicrobials, 
which in many cases are all that are available or affordable. Widespread selective pressure and 
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efficient dissemination channels for multidrug-resistant organisms are major factors that may 
have contributed to the rapid emergence and spread of resistant organisms.  
A pressing and unmet need exists to alter these factors in areas where susceptibility has been 
recorded and to identify other contributors to these alarming trends. 
National and international policy decisions backed by political and social will are necessary to 
provide a more accurate assessment of the problem and interrupt the unacceptable trends [71]. 
 
C. Clinical Spectrum  
 
Salmonella infection may appear to be one of several distinct clinical syndromes, or symptoms 
may overlap in its clinical presentation. The major disease states produced by salmonellosis 
are enterocolitis (gastroenteritis), enteric fever, bacteremia, focal infection and chronic carrier 
state [46]. 
a) Enterocolitis 
 
Localized acute intestinal infection is the most common form of salmonellosis. In the small 
intestine, epithelial invasion occurs but without extensive destruction of intestinal mucosa 
[72].  
The organisms reach the lamina propria where they multiply and elicit an inflammatory 
response. In 
S. typhi, this response may trigger production of predominantly mononuclear cells, whereas 
non-typhi 
Salmonella infection generally evokes polymorphonuclear neutrophilic reaction. It is also now 
known that colonic involvement occurs with acute salmonellosis (hence the term 
"enterocolitis"); histological changes include edema, inflammation, erosion and 
microabscesses [72,73]. 
Non-typhoid Salmonella serotypes, particularly S. Typhimurium, are most commonly 
responsible for acute enterocolitis. Although S. typhi may produce enterocolitis and cause 
diarrhea, constipation may be an equally or a more common gastrointestinal symptom with 
this strain of Salmonella. 
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Clinical expression of acute enterocolitis may occur as soon as 8 hours or as late as 72 hours 
following ingestion of Salmonella organisms. Symptoms may begin with transient nausea and 
vomiting followed by myalgia, headache, fevers, chills, diarrhea and abdominal cramps [74]. 
Generally, the stools are not bloody, are of moderate volume and loose in character. 
Occasionally, the disease may be severe, associated with fluid and electrolyte depletion 
leading to hypovolemic shock, blood loss, and toxic dilatation of the colon or bacteremia, 
particularly in those patients with increased susceptibility to salmonellosis. Symptoms of fever 
last less than 48 hours and diarrhea usually abates within one week, although patients with 
colonic involvement, intra-abdominal suppuration or other complications may have a 
prolonged course of fever, loose stools and abdominal complaints. 
Management will depend on severity of illness and any associated complications [75]. 
 
b) Enteric Fever 
 
Enteric fever is clinically caused by S. typhi and hence called typhoid fever. A clinical 
syndrome nearly identical to typhoid fever but caused by S. paratyphi A, B or C was 
previously designated paratyphoid fever. However, because other serotypes may also cause 
enteric fever, it is more conventional now to ascribe paratyphoid fever to any serotype other 
than S. typhi causing this syndrome [76]. 
Following ingestion of the organism, an incubation period of approximately ten days may be 
followed by bacteremia and the onset of the clinical features of enteric fever. Fever, chills, 
headache and gastrointestinal symptoms are the most important presenting complaints of 
patients with enteric fever. Interestingly, cough and bronchitic symptoms occur in more than 
half of the patients, but documented pneumonia is uncommon. A variety of other nonspecific 
complaints such as myalgia, arthralgia, weakness or sore throat may also occur. Physical 
findings are primarily limited to the abdomen [76]. 
Although paratyphoid fever is nearly identical to typhoid fever in its clinical features, relative 
bradycardia has been reported in 50 % to 100 % of cases. Neuropsychiatric manifestations of 
enteric fever are nonspecific but may occur in up to 75 % of patients [77,78]. Confusion, 
stupor and delirium are the most common findings, occurring in more than 50 % of cases. 
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Other diffuse and focal neurological deficits and gross schizophrenic psychoses have also been 
reported [77,78]. 
Complications of enteric fever, other than death, can be classified as abdominal or extra-
abdominal. 
Abdominal complications that are most serious are intestinal perforation (1-5 %) and intestinal 
hemorrhage (1-21 %). Complications occurring outside the abdomen include the 
neuropsychiatric features, localized infections (meningitis, endocarditis, arthritis, 
osteomyelitis, pneumonia), bone marrow suppression, parotitis, decubitus ulcer, renal failure 
and chronic carrier state. 
The antimicrobial chemotherapy that has been used to treat enteric fever has been primarily 
chloramphenicol, ampicillin or trimethoprimsulfamethoxazole [79]. 
Resistance to ampicillin may also occur, but less often than to chloramphenicol. 
Trimethoprimsulfamethoxazole resistance of S. typhi and other Salmonella species is 
uncommon even though resistance to sulfonamides alone may be present [79]. 
c) Chronic Carrier State 
 
The chronic carrier state is defined as the excretion of Salmonella for more than one year. 
Chronic enteric carriers who excrete organisms in the feces are the most common, although 
occasionally chronic urinary carriers are found. Chronic carriers are asymptomatic. The 
chronic carrier state occurs more frequently following S. typhi infection; the incidence is 2-
4%. 
Chronic carriers following non-typhoid salmonellosis is uncommon [80]. 
The chronic enteric carrier state of Salmonella increases with antigen and is associated with 
biliary tract disease. A chronic urinary carrier state is more commonly associated with 
schistosomiasis of the urinary tract. Management should be directed first toward determining 
the presence or absence of biliary tract disease. The antimicrobial drug of choice is ampicillin 
(not chloramphenicol, which has a poor success rate) [81].  
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D. Vaccines already available on the market 
 
a) The Vi polysaccharide vaccine 
 
The A subunit of S. typhi polysaccharide was developed as a vaccine in the 1980s in the 
laboratory of John Robbins at the NIH and licensed to Sanofi-Pasteur. The vaccine is based on 
purified Vi antigen, a linear homopolymer of galacturonic acid that is purified from the 
bacteria. It is produced by several manufacturers including developing country manufacturers. 
The vaccine is progressively introduced into school attending children vaccination programs 
in Asian countries [82] [83,84]. 
Its efficacy was demonstrated in multiple randomized trials. One of the first trials in Nepal 
involved persons antigened 5-44 years and showed a 75% protection antigenainst TF during 
20 months of active surveillance. Another study in South Africa demonstrated a 64% 
protective efficacy after 21 months in children antigened 5-16 years, declining to 55% at 3 
years after vaccination [85] [86]. A locally produced Vi vaccine prepared by the Shanghaï 
Institute of Biological Products, which was evaluated in a randomized placebo-controlled, 
double-blind trial on about 60 000 5-19 years old children in China showed a 69% efficacy 
antigenainst blood culture-confirmed TF over 19 months [87]. The Vi vaccine is considered to 
be protective for at least three years; it also has demonstrated a remarkable safety profile. 
Several high-quality producers from developing countries have acquired the technology to 
produce it at low cost, including two producers in China. 
Vi  is poorly immunogenic in infants and cannot be used to vaccinate children less than 2 
years of antigene. This has prompted the development of a Vi conjugate vaccine at the 
National Institutes of Health, USA, using recombinant Pseudomonas aeruginosa exotoxin A 
as the protein carrier (Vi-rEPA).  
 
b) The live attenuated Ty21a vaccine 
 
The attenuated S. typhi strain Ty21a was generated in Switzerland by chemical mutagenesis of 
wild-type strain Ty2 and developed as the first live oral typhoid fever vaccine. The strain is 
characterized as lacking both a functional galactose-epimerase (galE) gene and the Vi antigen, 
27 
 
although other mutations in the genome probably are responsible for the attenuated phenotype. 
The vaccine was extensively tested in Alexandria, Egypt, where the liquid formulation showed 
96% protection for 3 years, and in Santiantigeno, Chile, where it was found to elicit a 67% 
protection against blood culture-confirmed TF over 3 years and 62% over 7 years[88]. The 
liquid formulation was shown to be 78% protective at 5 years. Ty21a is therefore considered 
to provide protection for at least 5-7 years. The vaccine was less efficacious when tested in 
Indonesia, where protective efficacy was found to be only 33%-53%, suggesting that in-the-
field effectiveness in TF hyper-endemic areas, such as Indonesia, were quite lower than in 
areas with lower incidence of the disease, such as Egypt or Chile. In Chile, Ty21a also showed 
42%-56% cross-protection against paratyphoid fever caused by serovar Paratyphi B [89]. 
c) Other live attenuated S. typhi vaccines 
Several live attenuated S. typhi strains are being developed to be used as oral TF vaccines. In 
preliminary clinical trials, these strains seem to be even more immunogenic than Ty21a [90]. 
Perhaps the most advanced of these live attenuated candidate vaccines is Ty800, a phoP/phoQ 
deletion mutant of Ty2, which is developed by AVANT Immunotherapeutics [91] and has 
passed Phase II trials. The vaccine has been shown to stimulate vigorous IgA and serum O-
antibody responses in volunteers. 
Another attenuated strain is CVD909, an aroC/aroD/htrA deletion mutant which was 
engineered to constitutively express the S typhi Vi antigen. The strain, which induces anti-Vi 
antibodies in orally vaccinated subjects [92].  
The third live attenuated vaccine candidate is ZH09, a Salmonella Typhimurium strain deleted 
of the Salmonella pathogenicity island [93].  
A killed but metabolically active Salmonella Typhimurium strain, CKS362, is also being 
developed as a candidate Salmonella vaccine[94]. 
In addition, an attenuated S. typhi Ty2 strain with deletions in ssaV and aroC genes has been 
developed as a live vector (spi-VEC) for oral vaccines antigenainst TF and ETEC diarrhoea  
[95]. 
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d) Salmonella Native Outer Membrane Vesicles  
 
Salmonella spp produces Native Outer Membrane Vesicles (NOMV) containing OmpA and 
innate TLR ligands. Antigens in NOMV are protected from protease digestion and also 
recognized by antigen-specific T cells [96].  
NOMV contain TLR ligands and Salmonella T cell antigens, important findings that link 
NOMV properties with innate and adaptive host defense mechanisms. Little is known about 
the interactions of host-immune cells with NOMV, which may influence the development of 
Salmonella-specific immunity during infection in vivo[97] although relatively few studies 
have focused on NOMV produced by salmonellae [97]. 
Salmonella NOMV are proinflammatory and immunogenic facsimiles of the parental bacteria, 
and therefore could stimulate development of both innate and adaptive immunity as the ability 
of NOMV to stimulate responses for the activation of T cells, such as DC maturation (MHC-
II, CD86) and proinflammatory cytokine production (TNF-, IL-12)  [98].  
Salmonella NOMV possess important proinflammatory and antigenic properties similar to the 
parent bacteria and it is demonstrated that NOMV have the intrinsic combination of antigens 
and adjuvant properties required of an effective non-replicating complex vaccine to stimulate 
Salmonella immunity.  
NOMV could be an additional means to induce pathogen-specific immunity, and are therefore 
attractive vaccine candidates [99].  
29 
 
4. CELL ENVELOPE OF GRAM-NEGATIVE BACTERIA  
 
The hallmark of Gram-negative bacteria is their cell envelope, which is composed of two 
membranes (the inner and outer membranes) separated by a compartment (the periplasm) that 
contains a thin peptidoglycan (or murein) layer. Although both the inner and outer membranes 
are lipid bilayers that contain proteins, there are dramatic differences in their structure and 
composition, reflecting their different functions and the dissimilar environments that they 
contact [100]. 
The inner membrane (IM) is in direct contact with the cytoplasm and the periplasm, whereas 
the outer membrane (OM) separates the periplasm from the external environment. Because of 
its physical properties, the OM functions as a selective barrier that prevents the entry of many 
toxic molecules into the cell, a property that is crucial for bacterial survival in many 
environments [101]. 
All Gram-negative bacteria have an OM, and although there is some variation among different 
species, the overall structure and composition are largely conserved [101,102]. 
 
A. The inner membrane 
 
The IM is a bilayer composed of phospholipids and proteins. Although the phospholipid 
content varies between bacteria, in E. coli 70–80% is phosphatidylethanolamine, 15–20% 
phosphatidylglycerol and 5% or less cardiolipin [103]. IM proteins can be of two types, 
integral IM proteins and lipoproteins. Integral IM proteins span the IM with α-helical 
transmembrane domains, and lipoproteins are anchored to the outer leaflet of the IM by lipid 
modifications of the N-terminal cysteine residue of their mature form [104]. Many IM proteins 
function in small-molecule transport, but they also carry out various other cellular functions. 
All of the membrane-bound biochemical processes that occur in intracellular organelles in 
eukaryotic cells, such as oxidative phosphorylation, lipid biosynthesis and protein 
translocation, occur in the IM in bacteria. 
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B. The periplasm 
 
The periplasm comprises ~10% of the cell volume and is a highly viscous compartment that is 
occupied by soluble proteins and the peptidoglycan layer. The periplasm is an oxidizing 
environment, and it contains enzymes that catalyse the formation of di sulphide bonds [105].  
Periplasmic proteins participate in small-molecule transport or the breakdown of polymers to 
‘bite-size’ compounds [105]. However, many molecular events that are crucial for cell survival 
also occur in the periplasm.  Protein folding and trafficking factors that build and maintain the 
cell envelope, even in times of stress, are located here [106]. Furthermore, the sensing domains 
of most IM receptor proteins, such as the histidine kinases of most two-component systems, 
read environmental cues from this location. Remarkably, as the periplasm is devoid of ATP, 
all of this protein folding, trafficking and degradation occurs in the absence of an obvious 
energy source [107]. 
The peptidoglycan layer is located in the periplasm and serves as an extracytoplasmic 
cytoskeleton that contributes to cell shape and prevents cells from lysing in dilute 
environments. It is composed of glycan chains that are crosslinked by oligopeptides, but there 
are also proteins associated with the peptidoglycan layer as the Lpp (Braun’s lipoprotein) 
covalently anchors the peptidoglycan layer to the OM [108]. 
 
 
C. The outer membrane 
 
The OM is an unusual membrane in terms of its structure and composition. Unlike most other 
prokaryotic and eukaryotic membranes, it is highly asymmetric, with the inner leaflet 
composed of phospholipids and the outer leaflet composed mainly of LPS [109]. The overall 
phospholipid composition is slightly different from that of the IM, as the OM is enriched in 
saturated fatty acids and phosphatidyl ethanolamine [110,111]. 
LPS is composed of lipid A, a core oligo saccharide and an O-antigen polysaccharide of 
various lengths [112]. Many laboratory strains of E. coli lack O-antigen and mutants in the 
core ‘deep-rough’ mutants can be obtained. However, lipid A and the inner-core sugar KDO 
(3-deoxy-d-manno-oct-2-ulosonic acid) are essential for growth of E. coli. 
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LPS is essential for the barrier function of the OM, as was shown decades ago by the increased 
OM permeability of ‘deep rough’ mutants [113]. The strong lateral interactions between LPS 
molecules allow LPS to be highly compacted, giving the OM an almost gel-like appearance 
that is crucial for its barrier function. These interactions include interactions between fatty-
acid chains and between the sugar components [114]. 
In addition to lipids, there are two types of proteins in the OM, lipoproteins and integral Outer 
Membrane Proteins (OMPs). About 90% of all lipoproteins are located in the OM, where they 
are anchored to the inner leaflet in the same fashion as the lipoproteins anchored to the outer 
leaflet of the IM [104,114]. In fact, the N-terminal lipid modifications that are present in all 
membrane lipoproteins are made at the periplasmic face of the IM. By contrast, integral OMPs 
are different from integral IM proteins. Instead of having α-helical transmembrane domains, 
OMPs span the OM with amphipathic antiparallel β-strands that adopt a barrel like 
conformation which allows many of them to serve as channels [115]. As membranes are fairly 
impermeable to hydrophilic solutes, the channels that OMPs form are vital for the intake of 
nutrients and the excretion of toxic waste products. OMPs that do not function as channels can 
serve as enzymes as well as adhesins [115]. 
Furthermore, the OM contains other lipopolysaccharides, such as enterobacterial common 
antigen (ECA), and, under certain conditions, a polysaccharide capsule can be produced as an 
additional protective extracellular layer [116]. The OM also serves as the anchor for surface 
organelles such as pili that have a crucial role in pathogenesis [117] 
 
 
Figure 1. Cell envelope of gram-negative bacteria 
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D. Lipopolysaccharide (LPS) 
 
LPS is a complex glycolipid exclusively present in the outer leaflet of the OM of gram 
negative bacteria. It consists of a hydrophobic membrane anchor, lipid A, substituted with an 
oligosaccharide core region, which in some bacteria (e.g., in most E. coli strains, but not in the 
laboratory strain E. coli K-12 and also not in N. meningitidis) is extended with a repeating 
oligosaccharide, the O-antigen. These different LPS constituents are synthesized at the 
cytoplasmic leaflet of the IM. The lipid A moiety of LPS is rather well conserved among 
gram-negative bacteria. It usually consists of a β-1,6-linked d-glucosamine disaccharide 
carrying ester- and amide-linked 3-hydroxy fatty acids at the 2, 3, 2’, and 3’ positions and 
phosphate groups at the 1 and 4’ positions. The primary 3-hydroxy fatty acids may be 
substituted with secondary fatty acids. The lipid A biosynthetic pathway, also known as the 
Raetz Pathway [118], has been characterized in detail, mostly in E. coli and Salmonella 
Typhimurium, but it appears to be highly conserved among other gram-negative bacteria 
[118]. Remarkably, although LPS has so far only been detected in gram-negative bacteria, 
homologs of the genes encoding the lipid A biosynthetic enzymes have also been found in 
sequenced plant genomes [119]. 
The core oligosaccharide is much more variable between bacterial species. In addition, a huge 
amount of LPS heterogeneity is created by numerous modifications of both the lipid A part 
and the core part of LPS [120]. The modifying enzymes, which are localized in different 
cellular compartments, are not generally conserved thus different species can express uniquely 
modified types of LPS [121]. The O-antigen, if present, is the most variable part of LPS and 
shows even a high degree of variability between different strains of the same species [122]. 
 
 
Figure 2. Structure of Lipopolysaccaride 
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E. O-Antigen 
 
O-antigen, which is the most variable part of LPS, is composed of many repeats of O units. 
The variation of O-antigen lies in the sugar composition, the arrangement of the sugars, and 
the linkages between the sugars within the O unit as well as the linkages between O units 
[123]. O-antigen is an important component in the resistance to serum-mediated killing, 
phagocytosis, and killing by cationic peptides. O-antigen is synthesized separately before 
ligation to lipid A-core to form LPS. The O unit is synthesized by sequential transfer of sugars 
from respective sugar nucleotides to the carrier lipid, undecaprenol-phosphate (UndP) at the 
cytoplasmic side of the inner membrane. The O units are then translocated to the periplasmic 
side of the membrane by the O unit flippase Wzx and polymerized by Wzy to form a long 
chain O antigen before ligation to a preformed lipid A-core molecule [124]. 
O-antigen is highly immunogenic after immunization with whole cells or with LPS, the O-
antigen immunogenicity may depend on the adjuvant effect of the lipid-A. O-antigen, as it is a 
polysaccharide, elicits only T-cell-independent, that is, essentially antibody, responses. The 
antibody-antigen complex then activates the complement system, leading to the production of 
the MAC or to phagocytosis [125,126]. 
Some O-antigens resemble host components and probably facilitate invasion by mimicry of 
the host. 
Other O-antigens lead to specific interactions and perhaps act as adhesins.  Most O-antigen 
forms occur in several subspecies, indicating that there has been extensive transfer of genes 
involved in O-antigen biosynthesis, presumably due to selection of one O-antigen form over 
another [126].  
Many bacterial species have extensive variation in O-antigen structure and this polymorphism 
must be maintained by some form of balanced selection, such as niche-specific selection, with 
each clone having an O-antigen that is appropriate to its niche [127] . 
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5. GMMA: GENERALIZED MODULES FOR MEMBRANE ANTIGENS 
 
In NVGH to distinguish the naturally shed blebs to the detergent-derived vesicles [128]  we 
used the term GMMA (Generalized Modules for Membrane Antigens), indicating blebs 
released from the surface of living Gram-negative bacteria [123,129]. 
By electron microscopy, GMMA appear spherical with a bilayer membrane, electron-dense 
luminal content, and an average diameter of 50–250 nm, depending on the strain [130]. 
GMMA are pelletable from a cell-free supernatant and, due to their lipid content, GMMA will 
fractionate into lighter density fractions than soluble secreted proteins  [131].  
Biochemical analysis of density gradient-purified GMMA demonstrated that native GMMA 
consist only of the protein and lipids of the OM and periplasm and do not contain IM and 
cytoplasmic components [132]. Enrichment and exclusion of GMMA membrane and soluble 
cargo as compared with their concentrations in whole bacteria point to GMMA as a specific 
secretory mechanism. It is quite difficult to assess accurately the enrichment or exclusion of 
cargo. The localization of a protein in the whole cell influences its availability as GMMA 
cargo. For instance, a periplasmic protein that has affinity to the inner leaflet of the OM is 
more likely to appear “enriched” in GMMA when compared with the soluble periplasmic 
fraction of the whole cell, yet it may not be enriched when considering its concentration in the 
whole cell. Unfortunately, these affinities are often not known. Thus accurate 
enrichment/exclusion values are best determined by comparing the quantities of a component 
in GMMA and in whole cells relative to the quantities of other components [133]. 
 
 
Figure 3. GMMA release from gram negative bacteria 
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Vesiculation is an ubiquitous process for Gram-negative bacteria grown in a variety of 
environments including liquid culture, solid culture, and in biofilms [130]. In general, 0.2%–
0.5% of OM and periplasmic proteins are packaged in GMMA from E. coli and demonstrating 
that, OM GMMA formation and release is an energy sink [134]. In light of this, bacteria are 
unlikely to produce GMMA without function. In nonpathogenic bacteria, GMMA sometimes 
play a protective role. 
Although OM GMMA production has been observed for more than 50 years, the machinery 
that allows 
GMMA secretion while maintaining bacterial viability remains elusive. Many theories exist on 
the mechanism of vesiculation based on biochemical and genetic data and are reviewed 
elsewhere [135]. Based on budding events viewed by electron microscopy, outer membrane 
GMMA are thought to form when the OM bulges and pinches off, encapsulating soluble 
periplasmic cargo [136]. The maximum rate of GMMA production occurs during the end of 
log phase growth and, as documented for E.coli, Vibrio cholerae, and B. melitensis, and 
GMMA are abundant at sites of cell division [137].  
GMMA could be used as nutrient sensors and transporters, and their presence has been 
postulated to represent an alternative mechanism for survival in nutrient-limited systems [138]. 
Moreover, the release of GMMA increases when bacteria are exposed to conditions such as 
high temperature, exposure to antibiotics or serum, or nutrient deprivation [139]. 
GMMA from both intracellular and extracellular bacterial pathogens have been identified in 
diverse host tissues, revealing the ability of GMMA to access a variety of environments within 
the host.  
GMMA have also been detected in the fluids from infected hosts, demonstrating their ability 
to disseminate distant from the site of infection. The intracellular pathogen Salmonella 
Typhimurium secretes GMMA when growing intracellularly as well as into the supernatant of 
bacterial cultures [140].  
LPS serotype switching, oxygen stress, the availability of iron, and the presence of antibiotics 
are all pertinent to pathogenic bacteria living inside the host, and these conditions impact 
GMMA production, toxicity, and composition. Altering expression of LPS O-antigens is a 
well characterized defense strategy for pathogens to evade the host response [141] . 
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The presence and type of LPS O-antigen as well as the indirect effect of oxygen stress on the 
LPS structure may influence the physical ability of the membrane to bulge and initiate the 
formation of GMMA [142].    
 
A. Biogenesis of gram negative bacterial GMMA 
 
The mechanisms by which Gram-negative bacteria shed GMMA have not been fully 
determined, however some experiments suggest three models [143] : 
1. GMMA are generated by the loss of cell envelope integrity that occurs when the outer 
membrane expand more quickly than the underlying peptidoglycan layer 
2. Formation of GMMA is linked to the turgor pressure of the cell envelope, which 
changes with the accumulation of peptidoglycan in the periplasm 
3. Some signal molecules enhance the anionic repulsion between LPS by destabilizing 
the Mg2+ and Ca2+ salt bridges in the outer membrane, thereby causing membrane 
blebbing 
 
These three mechanisms may not mutually exclusive and may contribute collectively to the 
biogenesis of bacterial GMMA [143].  
However, the release of GMMA increases when bacteria are exposed to conditions such as 
high temperature, antibiotics or nutrient deprivation [138] . 
Alteration of the Tol-Pal system [123,129,144,145] increase the production of GMMA and it 
is a very attractive for rapidly recovering large amounts of GMMA from gram negative 
bacteria such as E.coli, Shigella spp and Salmonella spp [146,147] 
In some study is show that the peripalsmic production of soluble protein domains interact with 
the  Tol-Pal system, increasing the production of GMMA and it is very attractive for rapidly 
recovering large amounts of GMMA [147]. 
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Figure 4- Proposed models for biogenesis of Gram-negative bacterial GMMA. 
 
Model 1: GMMA originate from regions on the cell surface where 
peptidoglycan‐associated lipoproteins are missing due to the faster 
expansion of the outer membrane than the underlying peptidoglycan 
layer. 
Model 2: accumulation of peptidoglycan fragments in the periplasm 
causes increased turgor pressure, thereby increasing blebbing of 
theouter membrane. 
Model 3: ionic interactions between quinolone (PQS) and Mg2+ 
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B. Inter-bacterial activities 
 
Some bacteria use GMMA as an offensive tactic to gain a growth advantage over other 
bacteria. Protease and toxin-containing GMMA from E. coli, Shigella, Actinobacillus, 
Pseudomonas, and Borrelia, can interact with bacteria possibly via a fusion or adherence 
mechanism. GMMA proteins that can adhere to the external surface of the bacteria are 
associated with the external surface of GMMA. Proteins and lipids of the IM and cytosolic 
content are excluded from GMMA. GMMA are likely to bud at sites where the links between 
the peptidoglycan and OM are infrequent, absent, or broken [148,149]. 
The composition of GMMA from pathogens should reflect the state of the bacterial OM, and 
therefore depend on the site of culturing of the bacteria. Toxins associated with the external 
GMMA surface act as adhesins, for some GMMA, and the interaction between the toxin and 
the eukaryotic cell receptor governs subsequent uptake of the GMMA into the host cell.  
Binding of GMMA to host cells can also influence binding of bacteria to those cells.  This 
binding competes for bacterial cell receptors and may be due to outer membrane. Rather than 
inhibiting bacterial binding, GMMA enhance the adherence of the pathogen to the epithelial 
cells.  
GMMA have been proposed to act as long-range virulence factors that can protect luminal 
cargo from extracellular host proteases and penetrate into tissues more readily than the larger 
bacteria [150].  
 
C. Toxin transporters 
 
Active toxins are associated with several pathogen-derived GMMA and some of the toxins 
appear to be enriched in GMMA. In some cases, GMMA associated toxins are more active 
than the toxins alone, and some toxins are associated with the exterior surface of GMMA. The 
host cell response to the delivery of GMMA-associated toxin is likely to be quite different 
from that to the delivery of soluble toxin if the uptake of GMMA-associated toxin is 
coincident with the uptake with GMMA [151]. 
In addition to specific virulence factors, GMMA contain compounds that are recognized by 
eukaryotic cells in the innate and acquired immune response pathways. Considering that 
properties of the OM change during a bacterial infection (such as the O-antigen of LPS), the 
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impact of GMMA on the modulation of the immune system will also vary during the course of 
infection. 
This is not surprising since GMMA contain a natural adjuvant (endotoxin) and surface-
localized bacterial antigens. OMPs present in GMMA are all biologically active molecules 
that can activate immune cells via Toll-like receptors (TLRs) and induce leucocyte migration 
[152,153]. 
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6. NVGH PLATFORMS 
 
NVGH and NV&D are investigating the use of GMMA as new vaccines. NVGH has 
developed new methods to generate hyper-blebbing strains and to collect GMMA from 
bacterial suspensions, using two consecutive TFF steps (Tangential Flow Filtration steps: 
micro-filtration at 0.22 µm and thereafter a second micro-filtration at 0.1 µm) at the end of the 
fermentation process [104,114,129,154]. 
Release of GMMA is highly dependent on the envelope structure. Defect in proteins linkage 
the outer membrane to peptidoglycan layer or involved in a structural network between the 
inner, outer membranes and peptidoglycan layer result in the shedding of large amounts of 
GMMA. 
The Tol-Pal system is present in most of Gram-negative bacteria, it is required to maintain 
outer membrane integrity, a mutation in any of tol-pal genes confer a defect in other 
membrane integrity resulting in a major release of outer membrane GMMA 
[123,129,144,145,147,155]. 
NVGH, to over produce GMMA, is developing mutant strain deleting the tolR gene, which 
result in substantial overproduction of outer membrane particles without loss of membrane 
integrity [129,156]. 
NVGH has developed another innovative platform, describing a simplified methodology for 
extraction and purification of the O-antigen core portion of Salmonella lipopolysaccharide, 
suitable for large-scale production. Lipopolysaccharide extraction and delipidation are 
performed by acetic acid hydrolysis of whole bacterial culture and can take place directly in a 
bioreactor, without previous isolation and inactivation of bacteria. Further O-antigen core 
purification consists of rapid filtration and precipitation steps, without using enzymes or 
hazardous chemicals. The process was successfully applied to various Salmonella enterica 
serovars (paratyphi A, Typhimurium, and enteritidis), obtaining good yields of high-quality 
material, suitable for conjugate vaccine preparations [157].  
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III. PhD PROJECT AIM 
 
The purpose of my PhD project was to investigate the possibility to develop low cost vaccines 
applicable to Gram-negative strains, intended for neglected infectious diseases of 
impoverished communities, using the GMMA technology platform and the acid hydrolysis 
approach.  
This work showed the possibility to use GMMA particles as starting material for membrane 
components extraction, optimizing new and innovative platform developed according to the 
membrane component target nature, LPS or proteins, in order to decrease the costs of goods 
(COGs). 
The present work is focused on the O: 4,5-antigen polysaccharide extraction, purification and 
characterization from Salmonella Typhimurium SL1344 tolR
-
  GMMA.  
Following are shown the results obtaining from the O: 4,5-antigen molecules extracted and 
purified from  Salmonella Typhimurium SL1344 tolR
-
  biomass, Salmonella Typhimurium 
SL1344 tolR
-
  GMMA and Salmonella Typhimurium SL1344 Wild type biomass. 
The O: 4,5-antigen polysaccharide from GMMA, released  by  Salmonella Typhimurium 
SL1344 tolR
-
 ,was further characterized and compared with the Salmonella Typhimurium 
SL1344 Wild type O: 4,5-antigen structure . 
The electron microscopy approach was applied to study GMMA surface and particles 
interactions. 
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IV. MATERIALS AND METHODS 
 
1. Bacterial strains 
 
Salmonella Typhimurium SL 1344 was provided by the Welcome Trust Institute (NCBI 
Ref Seq: NC_003197.1).  
The tolR
-
of Salmonella Typhimurium SL 1344 was generated using a pAJD434 plasmid 
and the tolR gene was replaced with a Kan cassette encoding kanamycin resistance. 
The upstream and downstream regions of tolR were amplified by PCR with primers tolR1 
(CTAGTCTAGAGCCATCATTATTCCAGCGAAC) and tolR 
(AGCTTGATATCGGCTTACCCCTTGTTGCTTTC) for the upstream region and 
tolR3(AGCTTGATATCAGTCTGCGTCCCGTTGGCTT) and tolR4 
(CCGGGTACCGTTGCGCAGTTTTGCCGCT) for the downstream region, which 
contained restriction site at the 5’ and 3’ end (XbaI and EcoRV for the upstream and 
EcoRV and KpnI for the downstream region), to generate ~500-base pair (pb) long DNA 
fragments. These fragments were digested with the respective restriction enzyme (RE) and 
ligated to a previously XbaI and kpnI-digested pBlueScript18 (pBS) (quiagen) to generate 
a pBS containing 500pb upstream and downstream regions of tolR with a restriction site of 
EcoRV in the middle. This plasmid was digested with EcoRV and ligated to a kanamycin 
resistance cassette (kan
r
) previously amplified from pUC4K with primers tolR5 
(AGCTTGATATCAAAGCCACGTTGTGTCTCAAAATCTC) and tolR6 
(AGCTTGATATCTGAGGTCTGCCTCGTGAAGAAG), corresponding to the same 
EcoRV sites at both the 5’ and 3’ end, and digested with RE, to generate a plasmid 
containing the 500bp tolR upstream region, the kan
r  
cassette and the 500 bp tolR 
downstream region (pBS tolR 5’ kanr  tolR3’). This plasmid was linearized with an RE and 
linear DNA fragment was amplified by PCR with primers tolR1 and tolR4 to yield the 
DNA fragment tolR 5’ kanr  tolR3’. This fragment was electroporated into S.Typhimurium 
SL1344 expressing the phage λ red homologous recombination system encoded by 
plasmid pAJD434, and mutants where tolR gen was replaced with the kanr
 
resistance were 
selected on Luria-Bertani (LB) plates containing 25µg/ml kanamycin. Gene replacement 
was confirmed by PCR amplification of the genomic DNA of the mutant colonies using 
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primers tolR7 (CGCCGCTGCGCGTGAGGCGG) and tolR8 
(CCGCTTTCTTCGCGTCC) annealing upstream and downstream of tolR. 
  
2. Liquid growth media 
 
A. Complex media  
 
The complex media composition was: 30 g/L Yeast extract (BD, BD243621), 5 g/L KH2PO4 
(Sigma, P5655), 20g/L K2HPO4 (Sigma, P2222), 1M MgSO47H2O (Sigma, 63138), 5g/L 
Glycerol (Carlo Erba, 346161). 
B. Chemical defined media 
 
The Chemically Defined Media (CDM) composition was: 13.3 g/L KH2PO4 (Sigma, P5655), 4 
g/L (NH4)2HPO4 (Sigma, P215996), 1.7 g/L citric acid monohydrate (Sigma, C1909), 1M 
MgSO47H2O (Sigma, 63138), 1 mL/L Trace Elements, 1mL/L Vitamins and 3% Glycerol 
(Carlo Erba 346161), pH 6.7. Trace Elements solution contained: 2.5 g/L CoCl2 6H2O (Sigma, 
15862), 15 g/L MnCl2 4H2O (Sigma, M8054), 1.5 g/L CuCl2 H2O (Sigma, 307483), 3 g/L 
H3BO3 (Sigma, B9645), 2.5 g/L Na2MoO4 2H2O (Sigma, M1651), 2.5 g/L Zn (CH3COO) 2 
H2O (Sigma, 383058) and 100 mM ferric citrate (Sigma, F3388). Vitamins solution contained: 
0, 05 g/L thiamine (Sigma, T90344), 0, 01 g/L nicotinic acid (Sigma, N0761), 0, 01 g/L Ca-
panthotenate (Sigma, C8731) and 0, 01 g/L Pyridoxine-HCl (Sigma, P6280), 0,001g/L B12 
(Sigma, C3607).  
Glycerol was used as carbon source: 5g/L for shaker flask culture and 30g/L for fermentation 
process. 
Defined media could be supplemented with amino acids, 0.1g/L each: L-alanine (Sigma, 
A7469), L-arginine (Sigma, A8094),  L-aspartic acid (Sigma, A7219), L-asparagine (Sigma, 
A4159), L- cysteine (Sigma, C7352), L-glutamic (Sigma, G8415), L-Glutamine (Sigma, 
G8540), L-histidine (Sigma, H6034), L-isoleucine (Sigma, I7403), L-leucine (Sigma, L8912), 
L-lysine (Sigma, L5501), L-Methionine (Sigma, M5308), L-phenylalanine (Sigma, 
P5482), L-proline (Sigma, P5607), L-serine (Sigma, S4311), L-threonine (Sigma, T8441), L-
tryptophan (Sigma, T8941), L-tyrosine (Sigma, T8566), L-valine (Sigma, V0513).  
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C. Growth conditions in shaker flask 
 
Salmonella Typhimurium SL1344 wild type and Salmonella Typhimurium SL1344 tolR
- 
were 
grown in shaker flasks (Corning, 431401),  in 150 mL of complex medium, at 37°C (Thermo 
Scientific MaxQ 8000 stackable shakers) and shaking at 200 rpm. 
Salmonella Typhimurium SL1344 tolR
- 
 was grown in 125mL shaker flask (Corning,430421 ) 
using 30mL of chemical defined medium, 37°C, overnight and shaking at 200 rpm. 
Salmonella Typhimurium SL1344 tolR
-
  was grown in 500mL shaker flask (Corning, 431401) 
using 150mL of chemical defined medium, 37°C overnight and shaking  at 200 rpm. Defined 
medium was supplemented with L-histidine 0.1g/l, 0.3g/L, 0.6g/L. 
The cultures optical density (OD) was measured at 600 nm wavelength (Implen, OD600 
photometer) 
 
3. Fermentation conditions  
 
S. Typhimurium SL1344 wild type and S. Typhimurium SL1344 tolR
-  
were grown, up to 30 
OD, in 3L of chemically defined medium, using a 5L working volume fermenter (Sartorius B-
plus). 
Temperature was maintained at 37°C,  pH was fixed at 6.7 set point and controlled with 28% 
NH4OH (Sigma, 338818),  oxygen saturation was set at 30% and maintained  by agitation 
controller.  
Glycerol (30g/L) was used as carbon source and additional medium feedings with histidine 
(0,2g/L) were done. 
Antifoam polipropilenglicole (PPG) 0.25 g/L was added at the beginning of the fermentation 
process. 
The cultures optical density (OD) was measured at 600 nm wavelength (Implen OD600 
photometer). 
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4. TFF cassettes Pore size screening for GMMA recovery  
 
3L of S. Typhimurium SL1344 tolR- fermentation broth were processed through the 0.2 µm cut 
off Tangential Flow Filtration (TFF) membrane  (Sartorius, Sartocon Slice, Hydrosart, 0.1 m
2
, 
3051860701W) to divide bacteria biomass, in the retentate, form GMMA particles in the 
permeate, obtaining the “GMMA 0.2µm permeate” sample. 
1L of “GMMA 0.2µm permeate” was concentrate ten time (up to 100mL) using the 0.1 µm 
pore size TFF cassette (Sartorius, Sartocon Slice 200, PESU 0.02 m
2
, 3081545802W). The 
resulting retentate was washed with ten diafiltration steps, against PBS, maintaining the same 
volume and then collected obtaining the “GMMA 0.1µm retentate” sample.  
The permeate at the end of the 0.1µm TFF filtration step and the ten diafiltrations volumes 
were combined in a unique sample and subjected to a further TFF concentration step (up to 
100mL) using the 500 KDa membrane cassette (Pall, Centramate 0.019 m
2
, suspended screen 
channel, cod. 0S500C11P2). Sample was washed by ten diafiltration steps against PBS, 
maintaining the same volume and at, the end, the retentate was collected obtaining the 
“GMMA 500KDa retentate” sample. 
The 500kDa TFF permeate and the diafiltrations volumes were combined and subjected to 
another TFF concentration step (up to 100mL) through the 100KDa TFF cassette (Sartorius, 
Sartocon Slice 200, Hydrosart, 0.02 m
2
, 3081446802E). Sample was washed by ten 
diafiltration steps against PBS maintaining the same volume., at the end the retentate was 
collected obtaining the “GMMA 100KDa retentate” sample.  
The permeate resulting after the 100KDa TFF was subjected to another TFF concentration 
step, (up to 100mL) through the 30KDa TFF cassette (Sartorius, Sartocon Slice 200, Hydrosart, 
0.02 m
2
, 3081445902E) without diafiltration steps. The resulting retentate and permeate were 
both collected (fig.1). 
All samples were sterilized using the 0.22 µm filters (Corning, 431154) and stored at 4°C. 
20mL of all samples, at the end of each step, were ultracentrifuged for 2h, at 180000g and 4°C 
(Beckman coulture, L-90K, 45Ti-rotor). The resulting pellets were resuspended in 5 ml of 
PBS.  
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Figure 1: TFF cassettes Pore size screening for GMMA recovery from Salmonella 
Typhimurium SL1344 tolR
-
 .Experimental design 
 
5. LPS extraction using the hot phenol method 
 
A. Samples preparation 
a) Salmonella Typhimurium SL1344 wild type 
 
50 ml of Salmonella Typhimurium SL1344 wild type bacterial culture, grew up to 20 OD  in 
shaker flask (Corning, 431401) and in complex medium, were centrifuged for 20 minutes, at 
4000g and 4°C (Allegra X-15R, Beckman Coulter). The resulting pellet was resuspended in 
2ml of PBS (Phosphate Buffer Saline) to reconstitute the “Wild type BIOMASS Samples” 
(Figure 2). 
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Figure 2: Scheme of sample preparation from Salmonella typhimurium SL1344 wild 
type colture 
 
b) Salmonella Typhimurium SL1344 tolR – Biomass 
 
100 ml of Salmonella Typhimurium SL1344 tolR
-
 bacterial culture, grew up to 20 OD  in 
shaker flask (Corning, 431401) and in complex medium, were splitted in two 50 mL Falcon-
tubes and centrifuged for 20 minutes at 4000g and 4°C (Allegra X-15R, Beckman Coulter). 
The resulting pellet from one tube was resuspended in 2ml of PBS to reconstitute the “tolR-
BIOMASS sample” and the other one was resuspended  in 1 ml of PBS to reconstitute the 
“tolR-TOTAL sample” as descibed following (Fig. 3). 
 
c) Salmonella Typhimurium SL1344 tolR- GMMA 
 
The supernatant after the centrifugation of 100 mL of Salmonella Typhimurium SL1344 tolR
-
Bacterial cultures, at 20 OD, was divided in two high speed centrifuge tubes (50mL each) and 
spinned down by ultracentrifugation for 2 hours, at 180000g and 4°C (Optima L 90K 
Beckman Coulter, 45Ti-rotor). One of the resulting pellet was resuspended in 2 ml of PBS to 
reconstitute the “tolR- GMMA  sample” and the other one was resuspended in 1 ml of PBS and 
then mixed with the sample prepared before to constitute the “tolR-TOTAL sample” (Fig.3) 
 
 
S.typhimurium 
SL1344 wild type   
OD 20 culture 
Centrifuge 
4000g, 4°C, 20 ' 
Biomass pellet: 
resuspended in 
2mL of PBS 
Wild type 
BIOMASS 
sample 
Supernatant:  
waste 
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d) Salmonella Typhimurium SL1344 tolR-TOTAL: GMMA + BIOMASS 
 
The TOTAL sample was reconstituted  combining 1ml tolR
- 
BIOMASS sample with 1ml tolR
-
 
GMMA  sample (Fig.3). 
 
 
 
Figure 3. Scheme of samples preparation from Salmonella typhimurium SL1344 tolR-
colture 
 
B. Hot Phenol extraction of LPS 
 
500 µL of all samples were boiled 30-40 minutes in the thermo block at 100°C. 
1ug/uL of ProteinaseK (Promega, V302) was added in each sample and incubated at 60 °C 
overnight.  
An equal volume (500 µL) of saturated phenol solution at pH 8.0 (Sigma, P4557) was added 
and incubated for 3h at 70°C with occasional mixing. At the end, samples were centrifuged 90 
minutes, 15000g and 2°C (Allegra X-22R, Beckman Coulter). 
S.Typhimurium 
SL1344 tolR-  
OD 20 colture 
Centrifuge 20', 
4000g, 4°C 
Supernatant 
Ultracentrfifuge 
 2h 180 000g, 
4°C  
tolR- GMMA 
resusupended in 2mL of 
PBS: 
tolR- GMMA sample 
tolR- Biomass pellet 
resuspended  in 2mL of 
PBS 
tolR- BIOMASS 
sample 
Centrifuge 20', 
4000g, 4°C 
Supernatant 
Ultracentrifuge 
 2h, 180 000, 4°c 
tolR- GMMA pellet 
resuspended in  
1 mL of PBS 
tolR- Biomass pellet 
resuspended  in 1 mL of 
PBS 
tolR- Biomass pellet (1mL) 
+ 
tolR- GMMA pellett (1mL): 
tolR- TOTAL sample 
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The top water phase was recovered and 2 volumes of 100% ethanol (BDH Prolabo, 20821) 
were added. 
Samples were placed at -80°C for 90 minutes, to let the polysaccharide to precipitate.  
Samples were centrifuged 1h, 15000g and 4°C (Allegra X-22R, Beckman Coulter). 
The final pellets were lyophilized overnight and then resuspended, in the same initial volume 
of Milli-Q water. 
 
C. Acidic hydrolysis of LPS extracted using the Hot Phenol method 
 
1% Acetic acid (Carlo Erba, 302011) was added to the LPS samples, extracted as described 
before, to reach pH 4-4, 5 and thereafter were placed in a thermo block 90 minutes at 100°C. 
The solution was then neutralized by adding 28% NH4OH (Sigma, 338818) to reach a pH 
value of 6-7. 
Samples were centrifuged overnight at 15000xg and 4°C (Allegra X-22R, Beckman Coulter). 
Supernatants were collected and dialyzed, against water, using Slide-A-Lyzer with a 7 KDa 
cut-off membrane (Slide-A-Lyzer Dialysis Cassettes, 7K MWCO Thermofisher 66373).  
 
6. Direct acid hydrolysis on bacteria or GMMA samples for O-antigen 
release into the supernatant  
 
1% Acetic acid (Carlo Erba, 302011) was added directly to the sample (bacteria or GMMA 
samples) to reach pH 4-4, 5 and heating to 100°C for 6h. The hydrolysis was performed at 
2mL scale in 4mL Wheaton glass vials, using the boiling water bath. The hydrolysis, at 2L 
scale, was performed using a heat-jacketed glass round- bottom flask connected to a condenser. 
The resulting solution was neutralized adding 28% NH4OH (Sigma, 338818) to reach a pH 
value of 6-7. 
 
7. O:4.5-antigen purification process from S. Typhimurium SL1344 wild 
type 
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S. Typhimurium SL1344 wild type fermentation broth, at the end of the hydrolysis, was 
passed through a 0.2 µm TFF membrane (Sartorius, Sartocon Slice Hydrosart , 0.1 m
2
, 
3051860701W) (Figure 4). 
 
Figure 4. Flow chart for O-antigen extraction from S. Typhimurium SL1344 wild type 
S. Typhimurium SL1344 wild type was directly hydrolyzed at the end of the fermentation 
process and then pass through 0.2 TFF membrane, to divide the residual biomass from the 
permeate containing O-antigen.. 
 
2L of the resulting permeate were concentrated 10-folds by Tangential Flow Filtration using 
the 30KDa cut-off filter cassette (Sartorius, Sartocon Slice 200 Hydrosart, 0.02 m
2
, 
3081445902E). Twenty diafiltration, maintaining the same volume, were done to wash the 
sample (ten against 1 M NaCl and ten against water). The first 30KDa TFF retentate was 
collected.  
Citrate buffer (200 mM, pH 2.7) was added to 50mL of the first 30 KDa TFF sample, to give a 
final concentration of 20 mM, pH 3. The solution was mixed at room temperature for 30 min, 
further centrifuged (Beckman Allegra X-15R) for 30 min, 4000g at 4°C and the resulting pellet 
was discarded.  
The supernatant, containing O-antigen, was further purified by negative cationic exchange 
chromatography, using a Sartobind S MA75 filter (Sartorius) equilibrated with 20 mM citrate 
buffer at pH 3.  
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The flow-through, containing O-antigen, was collected and  500 mM Na2HPO4 (Sigma, 
S0876), absolute EtOH (BDH Prolabo 20821)  and 5 M CaCl2 (Sigma-C8106) were added, to 
give final concentrations of 25 mM Na2HPO4, 24% EtOH (v/v) and 200 mM CaCl2.The 
solution was mixed at room temperature for 30 min, centrifuged (Beckman Allegra X-15R)  at 
4000g, 4°C for 30 min, and the pellet was discarded.  
The resulting supernatant was passed through the PD-10 desalting column (GE Healthcare 
Life Sciences), in order to exchange the buffer with water, and analyzed. 
 
8. Comparison of four different O: 4,5-antigen purification processes 
starting from GMMA produced by S. Typhimurium SL1344 tolR–   
 
2L “GMMA 0.2µm permeate” sample, from Salmonella Typhimurium SL1344 tolR- 
fermentation broth processed with 0.2 µm TFF membrane, were treated with the acid 
hydrolysis approach (Fig.5). At the end of the hydrolysis this sample was centrifuged for 
20minuts, at 8000g, at 4°C (Beckman Coulter Avanti J-26 XP Centrifuge, JA-10 Fixed Angle 
Rotor), to divide the residual membrane fragments to the supernatant containing O-antigen. 
 
 
Figure 5. Flow chart for O-antigen extraction from GMMA produced by S. 
Typhimurium SL1344 tolR-. 
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The hydrolyzed GMMA material was concentrated 10-folds by TFF using the 30KDa cut-off 
filter cassette (Sartorius, Sartocon Slice 200 Hydrosart, 0.02 m2, 3081445902E). Twenty 
diafiltration, maintaining the same volume, were done to wash the sample (ten against 1 M 
NaCl and ten against water).The “first 30KDa retentate” sample was collected and used to test 
different purification schemes described ahead and summarized in the in Fig. 6 
 
 
9. Complete purification process for O:4.5-antigen  
 
50 ml of the first 30KDa retentate” was subjected to the same purification protocol used to 
purify the O:4.5-antigen from the biomass of S. Typhimurium SL1344 wild type 
biomass(Figure 6a). 
 
A. Precipitation with Citrate buffer followed by cationic exchange chromatography  
 
Citrate buffer (200 mM, pH 2.7) was added to 50 ml of the first 30KDa retentate to give a 
final concentration of 20 mM, pH 3. The resulting solution was mixed at room temperature for 
30 min. At the end of the mixing time, the solution was centrifuged (Beckman Allegra X-15R) 
for 30 min, 4000g, at 4°C. The pellet was discarded while the supernatant was collected and 
passed through the chromatographic filter Sartobind S MA75 filter (Sartorius), previously 
equilibrated with the same buffer (Citrate buffer 20 mM, pH 2.7). 
The filter flow through was collected and passed through the PD-10 desalting column (GE 
Healthcare Life Sciences), in order to exchange buffer with water, and analyzed. 
 
B. Precipitation with Citrate buffer followed by CaCl/EtOH precipitation 
 
Citrate buffer (200 mM, pH 2.7) was added to 50 ml of the first 30KDa retentate to give a 
final concentration of 20 mM, pH 3. The resulting solution was mixed at room temperature for 
30 min. At the end of the mixing time, the solution was centrifuged (Beckman Allegra X-15R) 
for 30 min, 4000g, at 4°C. The pellet was discarded while the supernatant was collected and 
added with 500 mM Na2HPO4, absolute EtOH and 5 M CaCl2 to give final concentrations of 
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25 mM Na2HPO4, 24% EtOH (v/v) and 200 mM CaCl2.The solution was mixed at room 
temperature for 30 min, centrifuged (Beckman Allegra X-15R) at 4000g, 4°C for 30 min and 
the pellet was discarded; the supernatant was collected, passed through a PD-10 desalting 
column (GE Healthcare Life Sciences) and analyzed (Figure 6c). 
C. Cationic exchange chromatography 
 
Citrate buffer (200 mM, pH 2.7) was added to 50 ml of the first 30KDa retentate to give a 
final concentration of 20 mM, pH 3. The resulting solution was immediately passed through 
Sartobind S MA75 filter (Sartorius), already conditioned with the same buffer (Citrate buffer 
20 mM, pH 2.7). The flow-through was passed through a PD-10 desalting column (GE 
Healthcare Life Sciences) and analyzed (Figure 6d).  
 
 
 
Figure 6. Four different schemes of  purification process for the O:4.5-antigen, starting 
from GMMA produced by S.typhimurium SL1344 tolR
-
; a) O:4.5-antigen purified using 
the standard purification protocol, developed starting from the biomass; b) Only the first 
precipitation step and the cationic exchange chromatography were tested; c) Precipitations 
with Citrate buffer and CaCl/EtOH were tested avoiding the cationic exchange 
chromatography; d) Only the cationic exchange chromatography was tested 
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10. Determination of the Total Sugar Content in Samples by the Phenol-
Sulfuric Assay 
 
Quantification of total sugar concentration in each sample was determined using the Phenol 
Sulfuric Acid Colorimetric Assay [158] 
Reagents: 
o 5% (w/v) Phenol solution (Sigma, P5566) 
o H2SO4 (Sigma, 84720) 
o 0.5 mg/mL Glucose solution (Sigma, 49158). 
In order to quantify the total sugar amount, sample concentration must be in the range of 
calibration curve, 62.5 - 250 µg/mL of Glucose. The calibration curve was made starting from 
0.5 mg/mL of Glucose standard solution. Each sample dilution (200 µL) was prepared in 
duplicate and 200 µL of water was used as blank solution. 
200 µL of Phenol solution and 1 mL of H2SO4 concentrated solution were added consecutively 
to each sample (blank solution, calibration curve, sample dilutions). All samples were 
incubated 10 minutes at room temperature, under chemical hood. Thereafter samples were 
mixed by Vortex and then incubated for further 30 minutes. At the end of the incubation time, 
samples were read at 490nm (Spectrophotometer Perkin Elmer Lambda 25). 
 
11. Determination of Protein Content by Micro BCA Protein Assay  
 
Protein content was measured by the Micro BCA Method (Thermo scientific Micro BCA 
Protein Assay Kit), following the manufacturer’s instructions.  
 
12. Estimation of DNA content by absorption at 260nm 
 
An estimation of µg/mL DNA concentration can be obtained multiplying by 50 the absorption 
value obtained reading the sample at 260 nm (Spectrophotometer: Perkin Elmer Lambda 25). 
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The Nucleic acids content was estimated measuring the absorbance at 260 nm, the maximum 
absorption wavelength of DNA. An overestimation could occur due to the presences of 
proteins or peptides, which absorbs at the same wavelength. 
 
13. Size exclusion chromatography 
 
A. TSK gel 3000 PWXL 
 
In order to estimate the molecular size distribution of O-antigen populations, samples were 
analyzed by HPLC- Size Exclusion Chromatography, using a TSK gel 3000 PWXL column 
(30 cm× 7.8 mm; particle size 7 µm, Tosoh Bioscience, 808021)  
The mobile phase was 100 mM NaCl (Sigma, S9888), 100 mM NaH2PO4 (Sigma, S8282), 5% 
CH3CN (Prolabo; 20060.320) pH 7 and the flow rate was of 0.5 mL/min. 
The refractive index detector was used to detect the O-antigens size distributions. 
The UV detector (A260) and fluorescence detector (ex280/em336 nm) were used to reveal 
peaks corresponding to impurities, like proteins and nucleic acids. 
 
B. Size exclusion chromatography on Sephacryl S-100 HR 16/60  
 
The purified O-antigen solution was loaded on Sephacryl S-100 HR 16/60 Gel Filtration 
column (16 x 600 mm; particle size 25 µm-75 µm; GE health care life sciences) using 10mM 
NaH2PO4, pH 7.2 as running buffer and a flow rate of 0.5 mL/min. 
 
14. HPAEC–PAD  
Rhamnose (Rha), galactose (Gal), glucose (Glc) and mannose (Man) are present once in each 
S. typhimurium O-antigen repeating unit, and N-acetyl glucosamine (GlcNAc), is present only 
in the core region. Their content in the purified O-antigen solution was estimated by HPAEC-
PAD after the monosaccharides release due to the acid hydrolysis. Commercial monomer 
sugars were used for preparation of calibration curves, for Rha (Fluka, 83650), Gal (Sigma, 
48259), Glc (Sigma, 49158) and Man (Sigma, 63580) quantification. O-antigen samples were 
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diluted to have each sugar monomer in the range 0.5-10 µg/mL , were hydrolyzed at 100°C for 
4 h in 2 M TFA(Sigma, 302031), conditions found to be optimal for release of all monomers 
without degradation. For GlcNAc quantification, O-antigen samples, diluted to have a GlcNAc 
(Sigma, a8625) concentration in the range 0.5-10 µg/mL, were hydrolyzed at 100°C for 6 h in 
1 M TFA, then cooled to 2-8°C for about 30 min and, dried using a vacuum centrifuge 
(SpeedVac) overnight. The following day they were, reconstituted in water and filtered using 
0.45 µm Acrodisc (PALL) filters before chromatographic analysis. 
HPAEC-PAD was performed using a Dionex ICS3000 instrument equipped with a CarboPac 
PA10 column (4x250 mm) coupled with PA10 guard column (4x50 mm). Separation of the 
sugars was performed with a flow rate of 1 mL/min eluting in a gradient from 10 mM NaOH 
to 18 mM NaOH over 20 min. After washing for 20 min with 100 mM AcONa in 28 mM 
NaOH, the column was re-equilibrated with 10 mM NaOH for 20 min. The effluent was 
monitored using an electrochemical detector in the pulse amperometric mode with a gold 
working electrode and an Ag/AgCl reference electrode. The Dionex standard quadruple-
potential waveform for carbohydrates was used. The resulting chromatographic data were 
processed using Chromeleon software 6.8. Calibration curves were built for each sugar 
monomer (0.5-10 µg/mL). The standards were hydrolyzed and analyzed in the same way as 
samples. For GlcNAc, glucosamine (GlcN) was the species detected by HPAEC-PAD after 
hydrolysis. 
 
15. ELECTRON MICROSCOPY  
A. Samples preparations 
 
S. Typhimurium SL1344 tolR
-
 was fermented up to 30 OD as described before. 
A small volume (100 µL) of fermentation broth of S. Typhimurium SL1344 tolR
-
 was 
collected and directly used to prepare the sample for Transmission Electron Microscopy 
(TEM) analysis. At the same time, 50 mL of the same fermentation broth of were centrifuged 
20 minutes at 4000g at 4°C (Allegra X-15R, Beckman Coulter) to divide the biomass from the 
supernatant containing GMMA.  
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The pellet obtained from biomass of S. Typhimurium SL1344 tolR
-
 was resuspended in 50 mL 
of PBS, 100 µL of this preparation were collected and prepared for TEM analysis.  
The Supernatant containing GMMA was ultra-centrifuged for 2 hours, at 180000g and 4°C 
(Optima L 90K Beckman Coulter, 45Ti-rotor). The resulting GMMA pellet was resuspended 
in 2 mL of PBS, obtaining the sample “GMMA before the 0.2 µm TFF”, 100 µL of this 
GMMA sample were treated for TEM analysis. 
 
 
B. Negative staining of GMMA 
 
Droplets of GMME suspensions (10 µL) were placed on formvar-carbon coated grids and 
allowed to adsorb for 60 sec. Excess liquid was removed gently touching the filter paper. The 
adsorbed specimen was then fixed for 2 min at room temperature floating on a drop of 4% 
paraformaldehyde plus 0.05% glutaraldehyde in PBS, pH 7.2. Negative-staining was 
performed by first washing the specimen grid on a drop of negative stain (2% uranyl acetate in 
distilled water), blotting and repeating this step once more, this time leaving the specimen grid 
for 60 sec on a new drop of negative stain solution.  
Samples were observed at a JEOL 1200 EX II electron microscope. Micrographs were 
acquired by the Olympus SIS VELETA CCD camera equipped the iTEM software. 
 
C. Transmission Electron Microscopy (TEM) of GMMA and bacteria 
 
For Transmission Electron Microscopy (TEM), samples were pre-fixed for 20 min at 4°C with 
2% paraformaldehyde + 2.5% glutaraldehyde in cacodylate sucrose buffer (0,1 M cacodylate, 
0,09 M sucrose, 0,01 M CaCl2, 0,01 M MgCl2, pH 6,9) containing 0,075% ruthenium red and 
0,075 M lysine acetate. After washing two changes for 30 min each at 4°C in the same buffer 
containing 0,075% ruthenium red, they were fixed with 2% paraformaldehyde+2,5% 
glutaraldehyde in cacodylate sucrose buffer containing 0,075% ruthenium red overnight at 
4°C. They were washed again, three changes for 30 min each at 4°C in the same buffer, and 
post-fixed with 2% osmium tetroxide in cacodylate buffer containing 0.075% ruthenium red 
for 1h at RT. Specimens were washed in the same buffer, three changes for 30 min each at 4°C 
and dehydrated in a graded ethanol series. Then samples were infiltrated for two days with 
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mixtures of LRWhite resin/ethanol in different percentages. At the end of the procedure, 
samples were embedded in LRWhite resin. Embedded material was cut with Reichert Ultracut 
ultramicrotome using a diamond knife. Thin sections (60-80 nm) were collected on copper 
grids, stained with uranyl acetate and lead citrate, and observed with a JEOL 1200 EX II 
electron microscope. Micrographs were acquired by the Olympus SIS VELETA CCD camera 
equipped the iTEM software 
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V. RESULTS 
 
In this study Salmonella Typhimurium SL1344 was chosen for production of generalized 
modules for membrane antigens (GMMA). The mutation of the tolR gene, that is part of the 
Tol-Pal system, important for the stability and integrity of the outer membrane, has been 
shown to increase the release of GMMA from the surface of other Gram negative bacteria into 
the culture medium. 
In this chapter, we describe the optimization of growth conditions for S. Typhimurium SL1344 
tolR
-
 strain to overproduce GMMA, released in the fermentation broth, and further purified, 
using different approaches. 
We show the possibility to use GMMA as O:4,5 -antigen extraction source, proposing an 
alternative purification protocol based on the GMMA characteristics and properties.  
We also characterize the GMMA O:4,5-antigen  structure to ensure the O:4,5 -antigen 
equivalence from GMMA with the O:4,5 -antigen from S. Typhimurium SL1344 wild type 
comparing the structure and the sugar composition 
 
1. Chemical defined medium Optimization for S. Typhimurium SL1344 
tolR- strain 
In this section we describe the strategies applied to optimize the chemical defined medium for 
S. Typhimurium SL 1344 tolR
-
 strain. 
To find the best growth condition, S. Typhimurium SL 1344 tolR
-
 was incubated overnight  
(37°C, shaking at 200 rpm) in chemical define medium (CDM) supplemented with different 
amino acids pools, using complex medium as control. 
The amino acids pool composition was based on the microbial metabolism and the related 
capacity to synthetize them starting from the same precursor.   
The amino acid pools were prepared in a stock solution, adding 0.1 g/L of each (Table 1). 
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POOL 
AMINO ACIDS 
COMPOSITION 
1 His, Ser, Cys, Gly 
2 Trp, Phe, Tyr 
3 Asp, Ala, Leu, Ile, Val 
4 Asn, Met, Lys, Thr 
5 Glu, Gln, Arg, Prol 
 
Table 1. Composition of different amino acids pools. 
Pool 1: histidine, serine, cysteine, glycine. 
Pool 2: tryptophan, phenylalanine, tyrosine. 
Pool 3: aspartate, alanine, leucine, isoleucine, valine. 
Pool 4: asparagine, methionine, lysine, threonine . 
Pool 5: glutamate, glutamine, arginine, proline. 
 
 
S. Typhimurium SL 1344 tolR
-
, after overnight incubation, was able to growth, from OD 0.04 
up to OD 0.26, only in presence of Pool 1 , thus for this strain one or more amino acid present 
in Pool 1 were necessary (Table 2). 
 
 
SAMPLES 
OD 
START 
OD 
 END 
Pool 1 0,04 0,26 
Pool 2 0,04 0,04 
Pool 3 0,04 0,04 
Pool 4 0,04 0,04 
Pool 5 0,04 0,04 
Complex medium 0,04 10 
 
Table 2. Growth condition in different amino acids pools. 
In order to identify the S. Typhimurium SL 1344 tolR
-
 auxotrophy, we decide to test different 
pools combination. 
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 As done before, S. Typhimurium SL 1344 tolR- was grown overnight at 37°C, shaking at 200 
rpm, in CDM supplemented with different Pools combination (see Table 3).           
                                             
POOL COMBINATION AMINO ACIDS COMPOSITION 
1\2 His, Ser, Cys, Gly,Trp, Phe, Tyr 
1\3 His, Ser, Cys, Gly Asp, Ala, Leu, Ile, Val 
1\4 His, Ser, Cys, Gly Asn, Met, Lys, Thr 
1\5 His, Ser, Cys, Gly Glu, Gln, Arg, Prol 
2\3 Trp, Phe, Tyr Asp, Ala, Leu, Ile, Val 
2\4 Trp, Phe, Tyr Asn, Met, Lys, Thr 
2\5 Trp, Phe, Tyr Glu, Gln, Arg, Prol 
3\4 Asp, Ala, Leu, Ile, Val Asn, Met, Lys, Thr 
3\5 Asp, Ala, Leu, Ile, Val Glu, Gln, Arg, Prol 
4\5 Asn, Met, Lys, Thr, Glu, Gln, Arg, Prol 
 
Table 3. Combination of the different amino acids Pools 
 
 
After 12 hours of incubation, S. Typhimurium SL 1344 tolR
-
 was able to grow, reaching the 
same OD value obtained in the Complex Medium, in the Pool 1 amino acids mix (Figure 1). 
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Figure 1. Salmonella Typhimurium SL1344 tolR
-
 growth curve in different Amino Acid 
Pool combinations. 
This strain showed the ability to grow only in defined media supplemented with Pool 1 amino 
acids. 
 
In order to identify the specific amino acidic auxotrophy, S. Typhimurium SL 1344 tolR
-
 was 
grown overnight, at 37°C and shaking at 200rpm in CDM supplemented with new Pools, 
obtained from different Pool 1 amino acids combinations, and using complex medium as 
control. 
New stock solutions (0.1 g/L each amino acid) were prepared using: histidine, serine, cysteine, 
glycine, tryptophan, phenylalanine and tyrosine (Table 4).  
 
 
 
POOL RECOMBINATION AMINO ACIDS COMPOSITION 
1R His, Ser, Cys, ,Trp, Phe, Tyr 
2R His, Ser, Cys, Trp, Tyr 
3R His, Ser, Cys, Phe, Tyr 
4R His, Ser, Cys,Trp, Phe, Tyr 
5R His, Cys, Trp, Tyr 
6R Ser, Cys, Trp, Tyr 
 
Table 4. Composition of different combination of amino acids present in Pool 1. 
 
 
S. Typhimurium SL1344 tolR
-
 growth curve was optimal only with amino acid combinations 
in which histidine was present, whereas in Pool 6R, composed only of serine, cysteine, 
tryptophan and tyrosine, bacteria was not able to grow (Figure 2). 
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Figure 2. Auxotrophy test, S. Typhimurium SL 1344 tolR
-
 growth curves in chemically-
defined media supplemented with amino acids. 
 
 
These results showed that, S. Typhimurium SL1344 tolR
-
 had an histidine auxotrophy. 
To create the best S. Typhimurium SL1344 tolR
-
 growth condition, the CDM was 
supplemented with different histidine concentrations: 0.1g/L, 0.3g/L, 0.6g/L. S. Typhimurium 
SL1344 tolR
-
  was incubated overnight at 37°C, shaking at 200rpm. 
At the end of the fermentation time no significant differences were found among the tested 
conditions (Figure 3). 
 
 
 
 
 
 
 
 
Figure 3. Salmonella Typhimurium SL1344 tolR- growth curve in CDM supplemented 
with different histidine concentrations. 
 
 
MEDIUM 
Composition 
STARTING 
OD 
FINAL 
OD 
CDM +  0.1 g/l His 0,05 10 
CDM +  0.3 g/l  His 0,05 11 
CDM +  0.6 g/l  His 0,05 13 
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This strain reached similar OD values adding 0.1 g/L, 0.3g/L or 0.6g/L hystidine to the CDM. 
Based on these results, S. Typhimurium SL1344 tolR
-
 showed an histidine auxotrophy and, for 
flask scale, the chemical defined medium could be supplemented with 0.1g/L histidine. 
To verify the scalability and robustness of the process, 3L batch fermentation, in a 5L 
fermenter, was performed using the CDM supplemented, at the starting point, with 0.1g/L 
histidine. 
 
 
 
 
Figure 4. Example of S. Typhimurium SL1344 tolR- fermentation batch. 
At OD 8, OD 16 and OD 30 stirrer decreased and the growth slowed down, this was due to the 
histine ending. Feedings,of 0.1g/L histidine, were necessary for growth restart. After the last 
histidine feed, at 15h and 30OD, S. Typhimurium SL1344 tolR
-
 performed the oxygen spike 
and the fermentation broth was harvested to collect GMMA. 
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During the fermentation process, at the 11
th
 hour with OD 8, the stirrer speed decreased and 
the pO2 saturation started to increase. This signal is generally associated with the strain 
suffering due to limiting growth factors, such as nutrient deprivation (Figure 4). 
We tried to add 0.1g/L of histidine and immediately after the feeding the stirrer started to 
increase and the pO2 saturation level returned up to 30%. 
The same situation, during the fermentation process, occurred at the 13
th
 hour with OD 16 and 
during the 15
th
 hour with 30 OD, and each time 0.1g/L of histidine was added (Figure 4). 
Histidine feedings allowed the S. Typhimurium SL 1344 tolR
-
 to continue to divide.  
After the last histidine feed (15
th
 fermentation hour) S. Typhimurium SL1344 tolR
-
, at 30 OD, 
produced an oxygen spike, signifying that the carbon source had been exhausted, and 
harvesting was performed (Figure 4). 
At the end of the fermentation process 3 histidine feedings were necessary to reach 30OD and 
to allow the oxygen spike to occur.  
To optimize the fermentation process for S. Typhimurium SL1344 tolR
-
, it might be possible 
to add all the histidine required at the beginning of the fermentation process. However, to 
increase the GMMA production and release it is better to grow the strain under stress 
conditions, like nutrient deprivation [158,159]. 
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2. O:4,5 Antigen extraction from S. Typhimurium SL1344 wild type, S. 
Typhimurium SL1344 tolR- and GMMA using the hot phenol method 
 
A. Hot phenol method optimization for high OD bacterial samples or GMMA  
 
Our purpose was to understand if, in GMMA particles, purified from S. Typhimurium SL1344 
tolR
-
, the concentrations of membrane components, such as LPS and proteins, were 
comparable to those in S Typhimurium SL13 44 wild type biomass, when both preparations 
were grown to the same OD. We chose, as the membrane component target molecule, the O: 
4,5-antigen. 
We used the hot phenol extraction method to purify LPS from GMMA particles and from wild 
type biomass, and further hydrolyzed the LPS using the acid hydrolysis approach. 
Adi Peleg et al. had previously optimized the LPS extraction protocol for culture grown up to 
OD 1.  
We introduced some variations into this protocol for our sample growth at high OD. The first 
variation, not present in the original protocol, was the preliminary treatment of the samples 
with Proteinase K in order to degrade membrane proteins (overnight incubation at 60°C). 
Another variable that was explored was the phenol incubation time (see materials and 
methods). 
Liquid phenol is an excellent proteins solvent [160] and its role as a deproteinizing agent is 
well established [161]. 
In the original protocol, the OD 1 samples were incubated 30 minutes with phenol to permit 
protein degradation. We tried prolonging the phenol incubation time up to 3h, in order for the 
protein components of high OD samples to be degraded. 
The removal of protein from the bacterial lysate is a crucial step in LPS extraction, and can be 
performed by the coprecipitation of proteins and nucleic acid in ethanol solution, avoiding the 
presence of both these contaminants in the final extracted LPS. 
We tried the LPS extraction method applying the modified protocol on S. Typhimurium 
SL1344
 
wild type and S. Typhimurium SL1344 tolR
-
, grown overnight, in complex medium, at 
37°C and 200 rpm shaking, up to 20 OD. 
67 
 
Samples were prepared, in duplicate sets, as described in the Materials and Methods and the 
LPS hot phenol extraction was performed. 
We extracted LPS, from one set of “S. Typhimurium SL1344 wild type biomass” sample, “ S. 
Typhimurium SL1344 tolR
-
 biomass” sample, “S. Typhimurium SL1344 tolR- GMMA” 
sample and “S. Typhimurium SL1344 tolR- TOTAL (biomass+GMMA)” sample. 
The other extraction set was used to prepare the “S. Typhimurium SL1344 tolR- TOTAL 2 
(LPS from biomass+ LPS from GMMA)” sample, composed of the LPS extracted from S. 
Typhimurium SL1344 tolR
- 
biomass and the LPS extracted from S. Typhimurium SL1344 
tolR
-
GMMA further collected and pooled. This sample was used as control. 
The acid hydrolysis approach was applied to all samples (1%Acetic Acid, 100°C, 1h and 30 
minutes) and the total sugar amount was quantified by the phenol sulfuric acid method. 
S. Typhimurium SL1344 wild type biomass and S. Typhimurium SL1344 tolR
-
biomass gave a 
similar sugar concentration (1455 µg/mL vs 1599 µg/mL) (Figure 5). 
GMMA from S. Typhimurium SL1344 tolR
- 
gave, surprising, a good amount of sugar, 
compared with S. Typhimurium SL1344 wild type biomass sample (941 µg/mL vs 1455 
µg/mL) (Figure 5). 
S. Typhimurium SL1344 tolR
-
 TOTAL 2 sample, composed of the combination of LPS 
extracted from GMMA and LPS from biomass, was expected to have the total sugar 
concentration consistent with the theoretical sum of single sugar concentrations found in S. 
Typhimurium SL1344 tolR
-
 GMMA (941 µg/mL) and in S. Typhimurium SL1344 tolR
-
 
biomass (1599 µg/mL). 
S. Typhimurium SL1344 tolR
-
 TOTAL 2 gave 2388 µg/mL of total sugar concentration, and 
this value was indeed comparable with the theoretical sum of LPS from GMMA and LPS from 
biomass (2540 µg/mL). Thus this sample can be consider our control with respect to the S. 
Typhimurium SL1344 tolR
-
 TOTAL sample, in which similar total sugar concentration was 
expected. 
S. Typhimurium SL1344 tolR
-
 TOTAL was composed by crude biomass and crude GMMA 
(see material and methods) and the LPS extraction was performed directly on this crude 
preparation. 
S. Typhimurium SL1344 tolR
-
 TOTAL showed a comparable total sugar concentration to S. 
Typhimurium SL1344 tolR
-
 TOTAL 2 sample, 2445 µg/mL vs 2388 µg/mL (Figure 5). 
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Based on these results, we were able to confirm that, the hot phenol extraction method worked 
well when applied to high culture ODs, rich in protein components, and following the new 
conditions (samples pretreatment with Proteinase K and prolonged phenol incubation time) 
that had been tested, the extraction can be performed directly on the total sample composed of 
crude GMMA and crude biomass. 
 
 
 
 
 
Figure 5. Optimization of the LPS hot phenol method extraction. 
LPS from S. Typhimurium SL1344 tolR
-
 TOTAL 2 sample was used as control. This sample 
derived from a combination of LPS extracted separately from GMMA and biomass and then 
mixed. Its concentration was similar to LPS extracted from S. Typhimurium SL1344 tolR
-
 
TOTAL, which is composed of crude GMMA and crude biomass- This  indicates that the hot 
phenol method is effective when directly applied to crude material with a comparable total 
sugar content. 
Total sugar concentration was quantified using the phenol sulfuric assay. 
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B. O4:5 - antigen purification on the LPS extracted using  the hot phenol method from 
S. Typhimurium SL 1344 wild type, S. Typhimurium SL1344 tolR- and GMMA  
 
In this section we show the results of analysis of O:4,5-antigen from S. Typhimurium SL 1344 
wild type and S. Typhimurium SL1344 tolR
-
 to understand the sugar populations present in 
these two different samples. 
LPS was purified using the optimized hot phenol method and further treated with the acid 
hydrolysis approach. 
S. Typhimurium SL1344 wild type and S. Typhimurium SL 1344 tolR
-
 were growth overnight, 
in complex medium, at 37°, 200 rpm shaking, up to 20 OD. 
Samples were prepared as described in materials and methods. 
The O:4,5-antigen portion of the LPS was cleaved, from lipid-A, using the acid hydrolysis 
approach (1%Acetic Acid, 100°C, 1h and 30minutes) .  
Each sample was analyzed in terms of total sugar concentration, using the phenol sulfuric 
assay, and in terms of O:4,5-antigen  population by size exclusion chromatography. 
S. Typhimurium SL1344 wild type biomass and S. Typhimurium SL1344 tolR
-
 biomass 
showed a similar sugar concentration: SL 1344 wild type biomass contaioned 1126 µg/mL 
sugars while SL1344  tolR
-
 biomass contained 1111 µg/mL (Figure 6). 
Another important confirmation was that, the total sugar amount found in GMMA sample was 
comparable with the S. Typhimurium SL1344 wild type biomass: SL1344 tolR
-
 GMMA gave 
874 µg/mL LPS vs SL 1344 wild type biomass 1126 µg/mL (Figure 6). 
The TOTAL sample, composed by S .Typhimurium SL1344 tolR- biomass and S. 
Typhimurium SL1344 tolR
-
 GMMA, showed the highest total sugar concentration of the 
various samples, including the S.Typhimurium SL1344 wild type biomass. 
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Figure 6. LPS extraction using the optimized hot phenol method for high OD samples. 
GMMA from S. Typhimurium SL1344 tolR- showed a comparable total sugar concentration to 
the S. Typhimurium SL1344 wild type biomass. In the S. Typhimurium SL1344 tolR
-
TOTAL 
sample was found the highest sugar amount, due to the presence of sugar  from sugar biomass 
and from GMMA particles. 
Total sugar quantify by the phenol sulfuric assay. 
 
All samples were loaded on HPLC-SEC columns to visualize the O:4,5-antigen  population 
distribution and contaminant (proteins and nucleic acids) profiles.  
The Refractive index channel showed the presence of three different O:4,5-antigen s 
populations, based on the elution time: High Molecular Weight (HMW), Medium Molecular 
Weight (MMW) and Low Molecular Weight (LMW). 
The S. Typhimurium SL1344 wild type biomass showed an enrichment in the High Molecular 
Weight O:4,5-antigen  peak with respect to LPS from the tolR
-
 samples (Figure 7). 
In GMMA from S. Typhimurium SL1344 tolR- was found an enrichment in the Medium 
Molecular Weight O:4,5-antigen  population (Figure 7). 
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S. Typhimurium SL1344 tolR
- 
biomass, S. Typhimurium SL1344 tolR
- 
GMMA and S. 
Typhimurium SL1344 tolR
- 
TOTAL (biomass+GMMA) showed a predominance of the MMW 
O:4,5-antigen  population  respect to the HMW (Figure 7). 
The florescence (260/Em 280 nm) and emission (214nm) channels revealed the presence of 
higher amounts of impurities in LPS from the S. Typhimurium SL1344 wild type sample 
compared with LPS from GMMA from S. Typhimurium SL1344 tolR- in terms of proteins and 
nucleic acids, indicating the purity of GMMA material respect the biomass. 
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Figure 7. HPLC-SEC TSKgel 3000 PWXL column. 
A) Refractive index channel: Only GMMA sample (green line), from S. Typhimurium SL1344 
tolR
-
, showed two distinct O:4,5-antigen  populations corresponding to the MMW and LMW. 
S. Typhimurium SL1344 Wild type sample (red line) showed an enrichment in HMW O:4,5-
antigen  population, corresponding with the lowest retention time peak. 
The GMMA sample presents an enrichment of the Medium Molecular Weight O:4,5-antigen  
in comparison with wild type. 
All tolR
-
 samples showed predominance in the MMW O:4,5-antigen over the HMW 
population 
B) Ex 260/Em 280 nm channel and  C) 260 nm channelRefractive Index channel showed that, 
GMMA from S. Typhimurium SL1344 tolR-- sample contained less impurities than the other 
samples. 
S. Typhimurium SL 1344 wild type: red line 
S. Typhimurium SL1344 tolR
- 
biomass: black line 
S. Typhimurium SL1344 tolR
- 
GMMA: green line 
S. Typhimurium SL1344 tolR
- 
TOTAL: light blue line 
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These results showed that, for GMMA from S. Typhimurium SL1344 tolR
- 
there was a 
comparable sugar amount to S. Typhimurium SL1344 wild type biomass. 
In GMMA particles there is a high concentration of membrane components and so GMMA 
could be used as a source of LPS and protein extraction and, in this case, an O4,5-antigen 
source. 
The main difference found between S. Typhimurium SL1344 wild type and S. Typhimurium 
SL1344 tolR
- 
GMMA was related to the O:4,5-antigen  populations. The GMMA sample from 
S. Typhimurium SL1344 tolR
-
 was enriched in MMW O:4,5-antigen with respect to the S. 
Typhimurium SL1344 wild type biomass, in which the HMW O:4,5-antigen  was the most 
abundant population. 
To verify these results and ensure reproducibility for our optimized protocol, this experiment 
was repeated, in parallel, 3 times (Figure 8). Samples showed a little variations in terms of 
total sugar concentration values but, calculating the relative coefficient of variation (Table 5), 
all samples showed a variability under the 15% thus our LPS hot phenol extraction protocol, 
optimized for high OD and GMMA, could be defined precise and accurate, in line with the 
FDA Guidance for Industry Bioanalytical, Method Validation (U.S. Department of Health and 
Human Services Food and Drug Administration Center for Drug Evaluation and Research 
(CDER) Center for Veterinary Medicine (CVM), May 2001). 
 
SAMPLE COEFFICIENT OF 
VARIATION 
S. Typhimurium SL 1344 wild type biomass 7,95 
S. Typhimurium SL 1344 tolR- biomass 8,69 
S. Typhimurium SL 1344 tolR- GMMA 5,24 
S. Typhimurium SL 1344 tolR- TOTAL (GMMA+biomass) 2,96 
 
Table 5. Coefficient of variation calculated on the different samples sets after the total 
sugar concentration estimation using the phenol sulfuric acid assay  
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Figure 8. Consistency tests to confirm the optimization of the high OD LPS hot phenol 
extraction method. 
Three different tests were performed individually in parallel. LPS was extracted using the 
optimized hot phenol extraction method. 
The total sugar concentration was consistent among the different samples  
(Coefficient of variation <10%) 
Total sugar concentration quantified using the phenol sulfuric assay. 
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3. O4:5- antigen extraction from S. Typhimurium SL1344 wild type, S. 
Typhimurium SL1344 tolR- and GMMA using the Direct Acid 
Hydrolysis approach  
 
In this section we describe the O:4,5-antigen  extraction and purification processes using the 
acid hydrolysis approach, proposed by Micoli et al, applied to Salmonella Typhimurium 
SL1344 wild type biomass, S. Typhimurium SL1344 tolR
- 
and GMMA. 
Samples were obtained from three fermentations performed separately but in parallel. 
S. Typhimurium SL1344 Wild type was grown in a 5L fermenter using 3L of CDM to reach 
30 OD, without amino acid feeding (as described in materials and method).  
The direct acid hydrolysis approach was applied directly to S. Typhimurium SL1344 Wild 
type fermentation broth harvested and put in 2L glass round- bottom flask, adding 1% of 
Acetic Acid and boiling at 100°C for 6h. Afterwards, the sample was neutralized to pH 6-6.5. 
the hydrolyzed material was passed through the 0.2 TFF membrane and the permeate, 
containing O:4,5-antigen , was collected.  
The same approach was applied for S. Typhimurium SL1344 tolR
- 
fermentation broth, in 
which biomass and GMMA were present. 2L of fermentation broth were harvested and 
hydrolyzed, using a 2L glass round- bottom flask, in acid condition at 100°C for 6h. At the 
end, the sample was neutralized to pH 6-6.5 and a 0.2µm TFF step was performed to collect 
the permeate, containing the O:4,5-antigen  from biomass and GMMA material. 
S. Typhimurium SL1344 tolR
- 
fermentation broth, from the parallel fermentation process made 
using another vessel, was processed using the 0.2 µm TFF membrane, to collect permeate 
containing GMMA. 2L of GMMA material was moved in a 2L glass round- bottom flask. 1% 
acetic acid was added and the sample was boiled at 100°C for 6h. At the end of the hydrolysis,  
this sample was centrifuged for 20 minutes, at 8000g, at 4°C (Beckman Coulter Avanti J-26 
XP Centrifuge, JA-10 Fixed Angle Rotor), to divide the residual membrane fragments from 
the supernatant containing O:4,5-antigen . 
After hydrolysis, samples were collected and analyzed in terms of total sugar content by 
Phenol Sulfuric Assay, peptide content by MicroBCA method and nucleic acid content by 
absorbance at 260 nm.  
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Sugar quantification showed that, GMMA from S. Typhimurium SL1344 tolR
- 
after acid 
hydrolysis had a comparable total sugar concentration to the hydrolyzed material from S. 
Typhimurium SL1344 Wild type (Figure 9). This was a very surprising result indicating that, 
the GMMA sample contains a high amount of membrane components and thus LPS and 
O:4,5-antigen. 
The S. Typhimurium SL1344 tolR
- 
TOTAL sample showed the highest sugar concentration 
and this was due to the presence of biomass and GMMA from which LPS was extracted. 
 
 
 
Figure 9. Direct acid hydrolysis approach to Salmonella Typhimurium SL1344 Wild Type 
S. Typhimurium SL1344 tolR
-
 total and GMMA from batch fermentation processes. 
In GMMA, from S. Typhimurium SL1344 tolR
-
, was found a comparable total sugar 
concentration to the wild type biomass. 
S. Typhimurium SL1344 tolR TOTAL showed the highest total sugar concentration to the 
other samples. 
Total sugar concentration quantified by the phenol sulfuric assay. 
 Coefficient of variation less 10%. 
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All samples were characterized in terms of impurities like nucleic acid content, by absorption 
at 260 nm, and protein concentration, using the Micro BCA assay.  
In terms of impurities, the hydrolyzed material from GMMA samples contains fewer 
impurities than the hydrolyzed material form S. Typhimurium SL1344 wild type biomasss and 
from S. Typhimurium SL1344 tolR- TOTAL (biomass+GMMA), especially related to the 
nucleic acid content (Table 5). 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Protein concentration and Nucleic Acid estimation in S. Typhimurium SL1344 
Wild type biomass, S. Typhimurium SL1344 tolR- TOTAL (biomass+GMMA) and 
GMMA samples. 
GMMA samples showed the lowest concentration of impurities compared with S. 
Typhimurium SL1344 Wild type biomass and S. Typhimurium SL1344 tolR- TOTAL, 
especially related to Nucleic acid content. 
 
 
These samples were loaded on HPLC-SEC columns to determine the O:4,5-antigen  profile. 
The Refractive Index detector revealed the presence of three different O:4,5-antigen 
populations. 
The hydrolyzed material from S. Typhimurium SL1344 wild type showed a main peak 
corresponding to the High Molecular Weight O:4,5-antigen  (HMW, Figure 10) and another 
one corresponding to Medium Molecular Weight O:4,5-antigen  (MMW). 
Sample Proteins 
concentration 
µg/mL 
NucleicAcid 
estimation 
(ABS 260nm) 
S. Typhimurium SL1344 Wild 
type biomass 
 
627,1 10,08 
S. Typhimurium SL1344 
tolR
- 
TOTAL (biomass+GMMA) 
 
526,4 12,71 
GMMA 57,9 0,03 
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The hydrolyzed material from GMMA showed a main peak corresponding to Medium 
Molecular Weight O:4,5-antigen  (MMW) and another one for the Low Molecular Weight 
O:4,5-antigen  (LMW) (Figure 10).  
S. Typhimurium SL1344 tolR
- 
TOTAL (biomass+GMMA) showed the same O:4,5-antigen  
population found in GMMA (Figure 10). 
The HPLC-SEC profile showed that, the main difference between S. Typhimurium SL1344 
wild type and S. Typhimurium SL1344 tolR
- 
samples, GMMA and TOTAL, was related to the 
O:4,5-antigen  population.  
In particular, S. Typhimurium SL1344 wild type biomass sample showed the predominance of 
the HMW O:4,5-antigen  population while in GMMA, from S. Typhimurium SL1344 tolR
-
, 
the main peaks were related to the MMW and LMW O:4,5-antigen  (Figure 10). 
 
 
Figure 10. HPLC-SEC TSKgel 3000 PWXL column, Refractive index channel. 
Wild type sample (blue line) showed an enrichment of HMW O:4,5-antigen  population, 
corresponding to the lowest retention time peak, respect the MMW population. All samples 
derived from S. Typhimurium SL1344 tolR
-
, GMMA (green line) and TOTAL (black line), 
showed predominance in the MMW O:4,5-antigen  respect the HMW population. 
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4. O:4,5-antigen  purification process from S. Typhimurium SL1344 wild 
type and S. Typhimurium SL1344 tolR- GMMA 
A. O:4,5-antigen  purification from S. Typhimurium SL1344 wild type  
 
O:4,5-antigen  from biomass of S. Typhimurium SL1344 wild type was purified, after acid 
hydrolysis, as described by Micoli et al.  
The standard purification protocol, developed for O:4,5-antigen  recovery from the biomass at 
the end of the fermentation process, consists in several steps necessary to remove impurities. 
First step is the 30KDa Tangential Flow Ultrafiltration. The resulting retentate is treated using 
200 mM citrate buffer at pH 3, which allows the co-precipitation of nucleic acids and proteins.  
This material is also passed through a cationic chromatographic filter (Sartobind S MA75), in 
order bind residual proteins. The resulting flow through is than treated with CaCl/EtOH buffer 
to promote the precipitation of the remaining impurities, especially nucleic acids. At the end, 
the purified O:4,5-antigen  contains less than 1% of proteins and nucleic acids [27,158,159].  
 
 
S. Typhimurium SL1344 
Wild type 
Sugar 
(ug/mL) 
Protein 
(ug/mL) 
Nucleic acid   
(ug/mL) 
% 
Protein 
% 
Nucleic 
acid 
first 30 KDa TFF 4580 822,6 2850 18 62,2 
      first citrate buffer precipitation 4692 90 800 1,9 17 
      Sartobind S MA75 4135 16,2 15,1 0,4 0,4 
      
second CaCl/EtOH precipitation 3250 6 13,2 0,2 0,4 
 
Table 6. O:4,5-antigen  Purification Process from biomass of S. Typhimurium SL1344 
Wild type. 
Purified O:4,5-antigen  contains less than 1% of impurities. 
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B. Comparison of four different O: 4,5-antigen purification processes starting from 
GMMA produced by S. Typhimurium SL1344 tolR- 
 
In this section we describe the O:4,5-antigen  purification process, already proposed by Micoli 
et al, applied to purification of O-antigen from  GMMA. 
We want to explore the possibility of using GMMA as an alternative O:4,5-antigen  source 
with respect the conventional bacterial biomass. 
In order to optimize the O:4,5-antigen  purification protocol from GMMA, we tested different 
purification conditions to increase the recovery in terms of sugar yield and to decrease 
processing time and relative costs. 
GMMA sample showed a starting sugar concentration (859 µg/mL) comparable with the S. 
Typhimurium SL 1344 wild type biomass. 
Even at the beginning of the purification protocol, GMMA showed a very low amount of 
impurities, especially in relation to nucleic acids (Table 7), which at the starting point were 
already less than 1%. 
Following step by step the standard O:4,5-antigen  purification process applied to GMMA 
samples we noted that, at the end of the precipitation steps, no pellets were found. This was 
probably due to the absence of enough proteins and nucleic acids necessary for the 
precipitation of visible pellets.  
Based on the nucleic acids estimation, very low levels of this contaminant were present in 
GMMA samples. Thus after the first 30KDa TFF and after the first precipitation step with 
citrate buffer, the amount remains approximately the same (Table7). 
 
S. Typhimurium SL1344 -tolR 
GMMA 
Sugar 
(ug /mL) 
Protein 
(ug/mL) 
Nucleic acids 
(ug/mL) 
% 
Protein 
% 
Nucleicacid 
first 30 KDa TFF 2471,8 211,6 9,05 8,6 0,4 
      first citrate buffer precipitation 2438,5 122,2 6,15 5 0,3 
      Sartobind S MA75 2060 8,1 5,46 0,4 0,3 
      second CaCl/EtOH precipitation 1542,04 6,8 4 0,4 0,3 
 
Table 7. Standard purification process applied to GMMA. 
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Sugar concentration was quantified by phenol sulfuric assay, residual peptide by micro-BCA 
and nucleic acid by A260. Percentage calculation related to the total sugar amount in the 
specific volume obtained during each step of the purification protocol 
A different scenario was found for residual proteins, where their content decreased drastically, 
by about 50%, at the end of the first precipitation step (Table 2) and another important 
reduction was found after the cationic exchange chromatography. 
Based on these results, we may argue that it could be possible to remove some purification 
steps from the standard original protocol. 
In order to confirm this hypothesis and to understand the better procedures in order to purify 
O:4,5-antigen  from GMMA, different purification strategies were applied to the retentate 
material, post 30KDa TFF (Figure 11).   
We comparde the final sugar concentration, obtained from the standard purification protocol 
applied on GMMA, with different combinations of the purification steps: 
 Only precipitation using the citrate buffer 
 Precipitation with citrate buffer in combination with cationic exchange 
chromatography 
 First precipitation step with citrate buffer followed directly by precipitation with 
CaCl/EtOH 
 Only the cationic exchange chromatography, using the Sartobins S MA75 filter 
(Figure11). 
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Figure 11. O:4,5-antigen  purification strategies starting from GMMA. 
Combinations of purification steps: a) GMMA sample was treated using the standard O:4,5-
antigen  purification protocol, already developed for the biomass; b) Only the first 
precipitation step and the cationic exchange chromatography were used; c) Citrate buffer and 
CaCl/EtOH precipitations were tried avoiding the Sartobind S; d) Only the cationic exchange 
chromatography was used 
 
 
The first precipitation step using the citrate buffer 20mM, was not sufficient to reduce 
significantly the residual proteins amount, therefore further optimization to remove impurities 
are necessary.  
A similar result was found using only the two precipitation steps (citrate buffer and 
CaCl/EtOH), avoiding the Sartobind S MA75 filter step. Also here the residual proteins and 
nucleic acid level remained high. 
The purification process worked better using the first precipitation step with citrate buffer 
20mM in combination with the cationic exchange chromatography. At the end of these two 
steps, the residual nucleic acid and proteins decreased dramatically and also a good sugar 
amount was obtained (Table 8). 
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Based on these results we tried only the Sartobind S MA75 filter, without the precipitation 
step. The retentate of 30KDa TFF after hydrolysis of GMMA was buffered with 20mM citrate 
and directly passed through the Sartobind S chromatographic filter, previously conditioned 
with the same buffer. A consistent decrease in terms of impurities was found. The total sugar 
amount in the flow through after cationic exchange chromatography was higher than the final 
sugar concentration in the standard purification protocol (Table 8). 
 
 
S. Typhimurium SL1344 -tolR 
GMMA 
Sugar 
(ug/mL) 
Protein 
(ug/mL) 
Nucleic acid  
(ug/mL) 
% 
Protein 
% 
Nucleic 
Acid 
Classic purification process 1542 6,8 4 0,4 0,3 
      First citrate buffer precipitation + 
second CaCl/EtOH precipitation 
1692 66,2 5,6 3,9 0,3 
      Only cationic exchange 
chromatography 
1772 5,1 3,3 0,3 0,2 
 
Table 8. Final sugar concentration comparison between the standard purification 
process and different purification step combinations.  
Sugars concentration was quantified by phenol sulfuric assay, residual peptide by micro-BCA 
and nucleic acid by A260. Percentage calculation related to the total sugar amount in the 
specific volume obtained during each step of the purification protocol 
 
Starting from GMMA, the purification protocol could be drastically reduced. Cationic 
exchange chromatography, previously conditioned with the citrate buffer, could be used as the 
only step necessary to remove all impurities and could be applied directly to the retentate after 
30KDa TFF. 
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5. O4:5- antigen from Salmonella Typhimurium SL1344 tolR- GMMA: 
characterization of the Medium Molecular Weigh population  
  
In order to ensure the equivalence of the O antigen from GMMA with the O antigen from S. 
Typhimurium SL1344 wild type [162,163], a comparison in terms of sugar composition and 
structure was performed. 
We have focused our attention on the MMW O:4,5-antigen  extracted from S. Typhimurium 
SL1344 tolR
-
  GMMA. 
Starting from GMMA, at the end of the standard purification protocol, a significant sugar 
decrease was found, due to the loss of the LMW O:4,5-antigen  population, as show in the 
HPLC-SEC profiles in Figure 12,  leaving MMW O:4,5-antigen as the predominant population. 
 
 
Figure 12. O 4,5-Antigen GMMA profiles 
a) O 4,5-antigen profile in GMMA sample before the purification process, three O:4,5-antigen  
populations were present, HMW, MMW and LMW 
b) O 4,5-antigen profile in GMMA sample, after the first 30KDa tangential flow ultrafiltration 
step the LMW O:4,5-antigen  population was completely lost 
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The O:4,5-antigen  mix, at the end of the purification protocol from GMMA, was loaded on 
Sephacryl S-100 HR 16/60 Gel Filtration column to separate the HMW population, present as 
a minimal portion, from the MMW O:4,5-antigen . 
Fractions corresponding to the MMW O:4,5-antigen  were collected, pooled and further 
characterized.  
 
 
Figure 13. O 4,5-Antigen GMMA profiles loaded on Sephacryl S-100 HR 16/60 Gel 
Filtration column. 
Purified O 4,5-antigen form GMMA was loaded on S-100 and the fractions corresponding to 
the HMW and MMW O:4,5-antigen  were collected and pooled 
 
 
 
Figure 14. MMW and HMW O 4,5-Antigen GMMA profiles loaded on HPLC-SEC 
(Refractive index detector) TSKgel 3000 PWXL column. 
Comparison among the purified O 4,5-antigen from GMMA (black line), the HMW  (blue line) 
and MMW (red line) pooled fractions from  Sephacryl S-100  column. This was a 
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confirmation of that, the corresponding fractions of the HMW and MMW O:4,5-antigen s 
were correctly pooled form the Sephacryl S-100  size exclusion chromatography. 
 
The pool containing the MMW O:4,5-antigen  from GMMA of S. Typhimurium SL1344 tolR
-
 
was analyzed by High-Performance Anion-Exchange Chromatography with Pulsed 
Amperometric Detection (HPAEC-PAD), to understand the structure and the similarities with 
S. Typhimurium SL1344 wild type. 
MMW O:4,5-antigen  from GMMA was found to contain galactose, rhamnose, mannose at a 
ratio of 1:1 but with a decreased level of glucosylation (relative to rhamnose). 
As expected, the chain composition of MMW O:4,5-antigen  from GMMA of S. Typhimurium 
SL1344 tolR- was found to be the same found in the wild type strain [162,163] (Table 9).  
 
 
 
 
 
 
 
          
 
                                             *: molar ratios relative to Rha 
 
Table 9: Sugar composition of Medium Molecular Weight O:4,5-antigen  from S. 
Typhimurium SL1344 tolR
-
 GMMA. Commercial standard for Abe is not available 
 
 
 
 
 
 
Sugar 
S. Typhimurium SL1344 tolR
-
 
GMMA* 
Rha 1 
Man 1 
Gal 1,08 
Glc 0,49 
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6. S. Typhimurium SL1344 tolR- GMMA: recovery process optimization 
 
NVGH has developed a new method for GMMA recovery at the end of the fermentation 
process with a tangential flow filtration step using a 0.2 µm membrane to remove bacteria 
from the culture supernatant, and a second tangential flow filtration step, with a 0.1 µm 
membrane, to concentrate GMMA and to remove soluble proteins [27,129,158,159]. 
In this paragraph, we describe the optimization of GMMA recovery process based on the TFF 
membrane cut off screening applicable on GMMA produced by S. Typhimurium SL1344 tolR
-
. 
In the published literature it is already reported that, Salmonella Typhimurium wild type 
produces GMMA with size in a range of 10 to 200 nm [164] . Thus, based on this information, 
to find the best condition for recovery of all GMMA after the first 0.2 µm TFF, we tested 
different TFF cut off membranes. 
S. Typhimurium SL1344 tolR
-
 was fermented as previously described. GMMA were collected 
at the end of the fermentation process using the 0.2 µm TFF membrane. 1L of the resulting 
permeate was processed using sequential TFF steps decreasing the membrane cut off: 0.1 µm 
 500KDa  100KDa  30KDa. 
To obtain more concentrate samples, 20mL from all  retentate (after 0.1µm, 500KDa, 100KDa 
and 30KDa) and only the 30 KDa permeate were  ultracentrifuged at 180 000g, 2h at 4°C. The 
resulting pellets were resuspended in 5 ml of PBS and further sterilized with a 0.2 µm filter 
(Millipore). 
Interesting results were found in the retentate and permeate from the 30KDa TFF step: no 
pellets were found in both samples after ultracentrifugation. The absence of GMMA pellets in 
the 30KDa retentate and perrmeate indicated that GMMA were not present in these samples. 
Therefore the 100KDa cut off membrane was able to retain GMMA. 
To extract O:4,5-antigen from each sample and to quantify the total sugar amount, 2mL from 
all samples resuspended in PBS was put in glass vials and treated with the direct acid 
hydrolysis approach (1% acetic acid, 100°C, 6h)  
The phenol sulfuric quantification showed that, GMMA in the 100KDa retentate had the 
highest total sugar concentration (516.53 ug/mL) compared with the other samples. In contrast, 
GMMA in the 0.1µm retentate showed the lowest (51.56 ug/mL) total sugar amount (Figure 
15).  
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These results suggest that some GMMA passed through both the 0.1 µm and 500KDa TFF 
membranes, probably this was due to a not uniform GMMA size distribution in the samples. 
The bigger GMMA were retained by the 0.1µm cassette, and particles with an intermediate 
size range were collected by the 500KDa membrane. Thus only the 100KDa TFF membrane 
was able to retain small sizes GMMA (for more details see the electron microscopy section). 
The comparison between the total sugar concentration found in the 0.2 µm permeate, 
containing all sizes of GMMA (851 ug/mL), and the sum of the total sugar amounts from each 
retentate were comparable (GMMA in the 100KDa retentate 516.53 ug/mL + GMMA in the 
500KDa retentate 187.11 ug/mL + GMMA in the 0.1µm retentate 51.56 ug/mL = 755ug/mL 
total ), so during the screening process more than the 90% of produced GMMA were 
recovered (Figure 15). 
 
 
Figure 15. GMMA after the 0.2 µm, 0.1 µm, 500KDa and 100KDa TFF steps. 
 Total Sugar concentration.  
The highest sugar concentration was found in the 100KDa retentate (purple).  
The 0.1 µm (red) and 500KDa (green) membranes were able to collect GMMA with a bigger 
diameter so the smallest particles were retained by the 100KDa membrane. 
In the GMMA 0.2 µm permeate (blue) all GMMA, with different sizes, were present. 
The total GMMA sugar quantity was similar to the sum of that present in the different 
retentates, indicating that, during the TFF process, 94% of produced GMMA were recovered. 
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We have demonstrated that, S. Typhimurium SL1344 tolR
-
 produces GMMA with different 
size and this is a crucial factor for the GMMA recovery process. The membrane cut off must 
be chosen for each strain based on the specific GMMA size, in order to collect all material 
maximizing the yield.  
The best choice in order to recover all GMMA produced by S. Typhimurium SL1344 tolR
-
, 
after the first 0.2 µm TFF step, is the 100KDa membrane. This was confirmed by the total 
sugar concentration found after the GMMA acid hydrolysis, at the end of this screening.  
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7. ELECTRON MICROSCOPY RESULTS 
 
At the end of fermentation process, 50 mL of S. Typhimurium SL1344 tolR
-
 bacterial culture 
were centrifuged to divide the biomass from the supernatant. The resulting biomass pellet was 
directly prepared and fixed to be visualized by Transmission Electron Microscopy. The 
supernatant was ultracentrifuged and the resulting pellet was resuspended in PBS to obtain the 
sample called as “GMMA before the 0.2 um TFF”, further treated for TEM visualization. 
As show in Figure 16, S. Typhimurium wild type strain shows a thick and straight outer 
membrane layer in direct contact with the periplasm. The OM, the periplasm and the IM form 
together a compact and well organized structure [165]. On the contrary, the S. Typhimurium 
SL1344 tolR
- 
bacterial cell showed an instable OM layer and an abundant periplasmic 
interlayer space. This interspace, between the OM and the IM, is not well organized as in the 
wild type strain. This was the consequence of the tolR gene deletion, which encode for a 
protein parts of the Tol-Pal system responsible to maintain the integrity of the outer 
membrane.   
 
 
 
Figure 16. S. Typhimurium wild type strain and S. Typhimurium SL1344 tolR
-
 bacterial 
cells. 
A) S. Typhimurium wild type bacterial cell shows a well-organized OM-periplasm-IM 
structure 
B) S. Typhimurium SL1344 tolR- shows a compromised cell envelope structure. 
Arrows indicates the membrane instability portions 
(ref. bar is 500 nm) 
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At the end of the S. Typhimurium SL1344 tolR
-
 fermentation process 100 µL of fermentation 
broth, composed by bacterial cells and GMMA, were collected and directly prepared for TEM 
analysis.  
We captured the nascent formation of GMMA on S. Typhimurium SL1344 tolR
-
 bacterial cells 
(Figure 17), showing the presence of these particles in different location on the bacteria 
surface. 
GAMMA releases occur along cell body and also in correspondence of the division septa 
(Figure 18), this phenomenon was already observed by Deatherage BL at al. in S. 
Typhimurium tolA
-
 mutant strains [166]. 
In Gram negative bacteria, the defective linkage between the Outer Membrane and the Inner 
Membrane influences the GMMA releases and, probably, this defective linkage modulates the 
GMMA production at the division septa [167] as shown in Figure 18. 
 
  
 
Figure 17. Nascent GMMA from S. Typhimurium SL1344 tolR
-
  bacteria along the cell 
body (ref. bar is 200nm). 
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Figure 18. GMMA release from S. Typhimurium SL1344 tolR
-
 along cell body and at 
division septa. Arrows indicate the nascent GMMA from division septa and along the cell 
body. (ref. bar is 200nm)  
 
 
 
The fermentation broth taken directly from the vessel, before any treatment and directly 
visualized by TEM microscope showed a complex preparation composed of a mixture of 
bacteria, GMMA and a relevant amount flagella, as shown in Figure 19. However, also in 
sample “GMMA before the 0.2 um TFF” (Figure 5), obtained after ultracentrifugation, a 
massive presence of flagella was observed. These results suggest that, during the growth of S. 
Typhimurium SL1344 tolR
-
, flagella are naturally released in the fermentation broth.  
The observation of “GMMA before the 0.2 um TFF” sample has shown a non-homogeneous 
composition not only due the presence of flagella but also due the massive presence of 
GMMA particles with a wide range in size distribution, as shown in Figure 20.  
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Figure 19. fermentation broth of S. Typhimurium SL1344 tolR
-
. 
Bacterial cell (yellow arrow), GMMA (red arrow) and flagella (blue arrow). 
 
 
 
 
Figure 20. GMMA before the 0.2 µm TFF sample. 
Flagella (blue arrow) and GMMA particles (red arrows) with different size 
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A. Negative Staining  
 
The negative staining approach was applied on all the retentate samples collected during the 
TFF cassettes Pore size screening for GMMA recovery, as described in materials and methods 
section. 
The “GMMA 0.1 µm retentate” sample (collected after the 0.1 µm pore size filter cassette 
TFF) showed a huge amount of flagella and also particles with an average size distribution of 
56 nm (size range: 25-132nm). GMMA and flagella, stick to each other, formed a sort of “grid 
structure” able to entrap GMMA particles, as shown in Figure 19.  
This interaction might affect the free passage of GMMA particles through the 0.2 µm and 0.1 
µm TFF membranes reducing the efficacy of the GMMA recovery thus the related processes. 
 
                                            
Figure 19. GMMA 0.1µm retentate sample (ref. bar is 200nm) 
 
The scenario was quite different in the “GMMA 500KDa retentate” and “GMMA 100KDa 
Retentate” samples, collected after the 500KDa and 100KDa pore size filter cassette TFF 
steps. Looking at these samples, the presence of flagella, in both samples, decreased 
dramatically respect to the “GMMA 0.1µm retentate” thus almost all flagella were retained 
during the 0.1 µm TFF step while the majority of GMMA passed through this cut-off 
membranes, confirming the suitable use of the 0.1 µm cut-off TFF as a good and rapid way to 
collect flagella. 
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The negative staining of the “GMMA 500KDa retentate” samples showed a particles size 
average of 36 nm, in a range from 20 nm to 97 nm (Figure 20). 
In “GMMA 100KDa retentate” sample the particles average size was 30 nm, with a range from 
17 nm to 48nm (Figure 21). 
Based on these results we can say that, S. Typhimurium SL1344 tolR
-
 strain produces GMMA 
with different size, in a range from 130 nm to 17 nm.  
The 100 KDa membrane cassette was able to retain quantitatively all different GMMA 
particles produced by S. Typhimurium SL1344 tolR
-
 strain, which passed, with a different 
ratio, through the 0.1µm and 500KDa cut-off membranes. This data confirms the results 
shown before, obtained by the total sugars quantification after the GMMA direct acid 
hydrolysis in the TFF cassettes Pore size screening for GMMA recovery section. 
In conclusion, S. Typhimurium SL1344 tolR 
- 
release preferentially small GMMA and the best 
TFF cassette to recover all particles, at the end of the fermentation process and after the first 
0.2 µm TFF step, is the 100 KDa cut-off membrane filter for tangential flow ultrafiltration. 
                            
 
 
 
Figure 20. GMMA 500KDa retentate sample (ref. bar is 200nm) 
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Figure 21. GMMA 100KDa retentate sample (ref. bar is 200nm) 
 
B. Transmission Electron Microscopy 
 
The observation using Transmission Electron Microscopy (TEM) was applied on “GMMA 0.1 
retentate”, “GMMA 500KDa retentate” and “GMMA 100KDa retentate” samples. 
Analyzing pictures from each sample, a curios structure was shown: small GMMA particles 
were found to be encapsulated in the inner space of a bigger one GMMA (Figure 22). 
The same scenario was found in each sample indicating that, GMMA forms a complex 
structure, interacting each other, and the smallest particles were encapsulated inside of a 
bigger GMMA.  
The origin of the mechanism,  which leads this phenomenon, and how GMMA particles 
interact to each other to form this structure, are still unknown thus further investigation are 
required. 
We also noted that, some GMMA particles born from the same outer membrane point and at 
this stage the single particles could fuse each other, interacting in an unknown manner, and 
making the “GEMMA inside GMMA” structure (Figure 23).  
Another plausible explanation could be related to the release of a big GMMA able to lead 
away other outer membrane portions, which remain in its internal space, forming particles 
(Figure 24).  
The explanation of the encapsulation phenomenon remains still unknown and further 
investigations are required. 
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Figure 22. The “GMMA inside GMMA” phenomenon. 
(in A and B ref. bar is 200nm; in C ref. bar is 100nm) 
 
 
 
Figure 23. GMMA particles from the same membrane point 
(ref. bar is 200nm) 
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Figure 24. Small GMMA encapsulated in the internal space of a bigger one GMMA. 
(ref. bar is 500nm) 
 
 
VI. GENERAL DISCUSSION 
 
1. Summary of Results 
 
In nature, Gram-negative bacteria normally shed parts of their outer membrane via membrane 
particles, these are usually known in literature as outer membrane vesicles. In NVGH, we have 
named these membrane particles as GMMA (Generalized Modules for Membrane Antigens) 
to distinguish them to the detergent extracted OMVs, which differ from native GMMA in 
composition and immunogenicity [168]. 
GMMA composition is representative of the bacterial outer membrane, their surface is 
composed of outer membrane proteins, lipopolysaccharide (LPS), phospholipids and soluble 
periplasmic proteins.  
The porpoise of my work was to demonstrate the possibility to use GMMA as a new source of 
immunogenic membrane components, like proteins and LPS, useful for vaccines development.  
I have chosen, as target membrane molecules, the LPS and in particular the O:4.5 antigens 
polysaccharide, extracted from GMMA produced by S. Tyhphimurium SL1344 tolR
-
 strain, in 
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which the knockout of tolR gene, promotes GMMA release by decreasing the outer membrane 
stability. 
The first step was to maximize the productivity of GMMA during the fermentation process, as 
well as their recovery from the fermentation broth. 
A chemically defined medium was formulated bespoke and optimized to create the best grow 
conditions for S. Tyhphimurium SL1344 tolR
-
 strain. Different conditions were tested and, at 
the end, this bacterial strain showed an auxotrophy for histidine thus without this amino acid S. 
Tyhphimurium SL1344 tolR
-
 is  not able to grow. 
S. Tyhphimurium SL1344 tolR
-
  was fermented in a 5L fermenter with 3L of working volume 
up to 30 OD and, after the oxygen spike, the harvest was performed. 
In parallel, the wild type strain was fermented, in the same conditions, without histidine 
feedings, up to 30 OD. 
NVGH has developed a new purification method to recover GMMA produced by different 
tolR- Gram negative strains, using two consecutive TFF steps. In the first step, the 0.2 µm cut-
off membrane is used to separate the biomass, which remains in the retentate, from the 
GMMA particles that pass through the filter cassette in the permeate. 
The permeate is then further passed through another TFF filter membrane with 0.1 µm cut-off, 
necessary to separate GMMA particles, which remains in the retentate, from soluble proteins 
that pass through the filter cassette in the permeate.   
GMMA from S. Tyhphimurium SL1344 tolR
-
 were collected using the new method developed 
in NVGH but the process was further optimized in order to maximize the GMMA yield. 
To optimize the GMMA recovery process the key factor is the second TFF step. The 
membrane cut-off must be chosen respect GMMA sizes [165] and must be able to retain, as 
much as possible, GMMA particles. 
We tested different cut-off membranes (0.1 µm, 500 KDa and 100 KDa) in order to know the 
best one able to retain all GMMA particles produced by S. Tyhphimurium SL1344 tolR
-
Satisfactory result was obtained using the 100 KDa cut-off membrane, with a GMMA 
particles retention more than 90%. 
In conclusion, GMMA particles could be produced, from S. Tyhphimurium SL1344 tolR
-
, 
during batch fermentation process in CDM supplemented with histidine, and the GMMA 
recovery process could be simple and fast using only two consecutives TFF steps. 
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To characterize the O:4,5-antigen of S. Tyhphimurium SL1344 tolR
-
 GMMA and also to have 
a comparison with the S. Tyhphimurium SL1344 wild type polysaccharide, LPS was extracted 
from GMMA and from the wild type biomass using the hot phenol method, optimized for high 
OD bacterial culture and for GMMA samples. The O-antigen was cleaved from the extracted 
LPS using the acid hydrolysis approach. The total sugars quantification, in the hydrolyzed 
samples, was done using the phenol sulfuric assay. The total sugar concentration, after 
extraction and hydrolysis, in the S. Tyhphimurium SL1344 wild type biomass was comparable 
with the total sugar concentration observed in GMMA, obtained from S. Tyhphimurium 
SL1344 tolR
-
. 
The hot phenol extraction method is known to be the best choice for the LPS recovery but it 
can be applied only for a small samples volume due the severe toxicity of phenol, not 
applicable to industrial process. 
Recently, Micoli et al. have proposed an alternative method for the O-antigen extraction 
method directly from the biomass, avoiding the phenol use [165,169].  The method consists 
essentially in a direct acid hydrolysis of the bacterial culture, at the end of fermentation 
process, for 6 hours at 100°C. In these conditions, the O-antigen is cleaved from the Lipid A 
and released in the fermentation broth. These conditions were tested on GMMA sample to 
extract O:4,5 -antigen polysaccharides, which could be used to generate glycoconjugates 
vaccine [27,165]. 
The same analytical comparison made for the O:4,5-antigen extracted using the hot phenol 
method was done on GMMA recovered form S. Tyhphimurium SL1344 tolR
-
 fermentation 
broth and on the biomass from S. Tyhphimurium SL1344 wild type, both treated with the 
direct acid hydrolysis method. 
The total sugar quantification by phenol sulfuric assay was done, on both hydrolyzed samples, 
and a comparable concentration was found, indicating that GMMA are enriched in membrane 
components like LPS and therefore O-Antigens. 
Another important advantage of using GMMA, as O-Antigens source, is related to the 
purification method after the hydrolysis. 
The standard O-antigen purification protocol, proposed by Micoli et al, consists in several 
steps necessary to remove, from the hydrolyzed material, residual nucleic acids and proteins. 
Usually the final residual impurities concentration must be less than 1%. 
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The standard O-antigen purification protocol was applied on the hydrolyzed GMMA samples  
from S. Tyhphimurium SL1344 tolR
-
 and on S. Tyhphimurium SL1344 wild type biomass, to 
have a purification processes comparison starting from different materials. 
In the hydrolyzed material from S. Tyhphimurium SL1344 wild type biomass was found, as 
expected, a huge proteins and nucleic acids concentration which must be removed during the 
purification protocol, to obtain the polysaccharide with the expected purity. 
In the hydrolyzed material from GMMA, since the beginning, a low amount of impurities was 
found, especially regard nucleic acid, thus the purification process could be significantly 
simplified avoiding several costly purification steps, necessary in the purification protocol 
developed for the biomass. 
We tested on the hydrolyzed material of GMMA the standard purification protocol as well as 
other protocols, removing one or more purification steps. Due to the low percentage of 
impurities present in the hydrolyzed GMMA, several purification steps were not necessary to 
obtain the O-antigen with the expected purity. Only the chromatographic step (cationic 
exchange chromatography) was required to remove all residual proteins. 
Therefore, starting from GMMA, as O-antigen source, the purification protocol could be 
significantly reduced, diminishing time and costs relative to the entire process. 
I wanted also check the composition and structure of the O-Antigens obtained from the two 
different starting materials (GMMA from S. Tyhphimurium SL1344 tolR
-
 in comparison with 
the biomass from S. Tyhphimurium SL1344 wild type) and using different purification 
protocols. 
At the end of the purification process, the O-antigen from GMMA was analyzed by HPLC-
SEC and three different populations were found: O:4.5 antigen High Molecular Weight 
(HMW), O:4.5 antigen Medium Molecular Weight (MMW) and O:4.5 antigen Low Molecular 
Weight (LMW). The MMW and the LMW O-antigens populations were much more abundant 
than the HMW while in the S. Tyhphimurium SL1344 wild type biomass, enrichment in terms 
of HMW was found, respect the MMW population.  
The MMW O: 4.5 antigen from GMMA of S. Tyhphimurium SL1344 tolR
-
 was extracted, 
purified and further characterized to compare its composition respect the O:4,5-antigen  from 
S. Tyhphimurium SL1344 wild type. 
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In the MMW O: 4.5-antigen from GMMA was found galactose, rhamnose, mannose in the 
ratio 1:1 as the structure of O:4,5-antigen from the wild type strain . The only one difference 
was found in the glucosylation level. In the MMW O:4.5 antigen from GMMA was found less 
glucose (relative to rhamnose) than in the O:4.5 antigen from the wild type strain. 
In conclusion:  
o GMMA particles could be used as O-antigens source (and in general as source of 
membrane components) due their membrane composition enriched in LPS; 
o O-antigens can be extracted from GMMA using the direct acidic hydrolysis method, 
avoiding all issues related to the toxicity of the phenol, commonly used for the LPS 
extraction;  
o O-antigen from GMMA is composed predominantly by the Medium Molecular Weight 
(MMW) population; 
o O-antigen from GMMA has the same structure observed in the wild type strain;  
o The O-antigen purification process starting from GMMA is much more easy and cost 
effective than from the biomass. 
Using the electron microscopy approach on S. Typhimurium SL1344 tolR
-
 strain we have 
capture the nascent GMMA during the bacteria growth.  
We have found that, GMMA particles release occurred along cell body and also at the division 
septa. During the bacterial duplication event, the Tol-Pal complex migrates to the division 
septa modulating GMMA production and release from this specific point [165,166]. 
During the S. Typhimurium SL1344 tolR
-
 GMMA recovery process optimization, reported in 
the results section, the best condition for high GMMA recovery yield was obtained using the 
100KDa cut off TFF membrane, due to the relationship between GMMA size and membrane 
cut off.  
The “GMMA 0.1 µm retentate” sample showed a huge amount of flagella which interact with 
GMMA, forming a sort of “grid structure”. This TFF approach, useless for GMMA recovery, 
could be used to purify flagella from the fermentation broth, a similar approach has been 
already proposed by Oliveira et al. Some molecules could be extracted directly from bacterial 
flagella, an example of this application is the flagellin protein, which is used in diverse 
biotechnological applications, such as vaccine adjuvant and cellular protector during chemo- 
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and radiotherapy (Oliveira H. et al; Brazilian Journal of Chemical Engineering; Vol. 28, No. 
04, pp. 575 -584, October - December, 2011) 
Another important aspect found using the electron microscopy approach was related to the 
GMMA encapsulation forming the structure “GMMA inside GMMA”. 
In all samples were found small GMMA contained in the inner portion of a big GMMA. The 
mechanism which leads this phenomenon is unknown but we have some hypothesis: the outer 
membrane instability promotes the GMMA release so the outer membrane rearrangement 
could provoke the encapsulation of small GMMA into other GMMA; more GMMA produced 
from the same outer membrane point interacts each other, fusing their membrane and creating 
these structures. However, the reason of this phenomenon is already unknown and further 
experiments are required. 
GMMA could be used as vaccines itself, exploiting their properties as immune stimulator, due 
to the LPS and OM proteins exposition on their external surface. This GMMA peculiarity is 
very important for vaccines development. 
We have no information about the antigen molecules orientation in GMMA produced by S. 
Typhimurium SL1344 tolR
-
,  especially for small particles encapsulated in the internal space 
of a bigger one GMMA.  
The possible risk related with the structure “GMMA inside GMMA” is the membrane 
rearrangement which could influence the antigen molecules orientation, switching the external 
portion of the outer membrane to the opposite side, relocating the outer membrane proteins 
and LPS in the GMMA inner space, influencing the GMMA-host interaction, with a possible 
negative impact on vaccines development. To define the outer membrane orientation and to 
visualize the LPS exposition on our GMMA surface we are currently work on Immune Golden 
Labeling assay optimized for GMMA preparation. 
In literature is already reported that, the site of nascent GMMA release may also manipulate 
the GMMA protein constituents. Proteins in septal and cell body derived GMMA were 
identified by LC-MS/MS and quantified. Significant differences in the abundance of specific 
proteins in each GMMA population were identified at a 90% confidence level. Representative 
results are reported from two independent experiments demonstrating that specific proteins are 
differentially represented in GMMA released at septa or from cell body locations. For 
example, TolB, known to migrate to division septa during constriction was highly enriched in 
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septal GMMA. Cell body-derived GMMA, however, were enriched in the flagellar cap and 
hook/filament junction proteins FliD and FlgK [166].  
The specific protein enrichment in different kinds of GMMA is another important point, if 
GMMA particles wants to be used as vaccines itself, could be possible define where the target 
immunogenic protein is expressed and could be possible select, by size, the specific GMMA 
population. Using this approach could be possible the development of a more specific GMMA 
based vaccines. 
 
2. Implication for Vaccines Development  
 
The same approach used and developed for S. Tyhphimurium SL1344 tolR
-
 could be applied 
to other gram negative strains to purify membrane components as polysaccharides or proteins. 
This new method for purification of O-antigens used to develop a glyconiugate vaccine is the 
connection between two technology platforms: the direct acid hydrolysis approach developed 
to purify O-Antigens directly from the biomass, and the GMMA particles used as vaccines.  
The direct consequence of this new paradigm is the significant decrease of Cost of Goods 
connected with the entire manufacturing process. 
We would develop and facilitate the introduction of new cost effective vaccines to diminish 
the susceptibility of disadvantaged populations to the predominant enteric pathogens 
responsible for pediatric mortality and severe morbidity [170,171]. 
We would promote vaccination against diseases which causes thousands of children death 
especially in developing countries, like diarrhea which is one of the most common causes of 
morbidity and mortality in children worldwide  [172,173]. 
GMMA particles could belong in this context.  
GMMA could be used not only as membrane component source but also to develop broad 
spectrum vaccines due to the complexity of the outer membrane molecule. 
NVGH is developing a new broad spectrum GMMA based vaccines against Shigella spp, 
exploiting their antigenic properties, using the entire particle to induce an immune response. 
Clinical trials are still on going to ensure vaccines efficacy and safety. 
GMMA particles could be used also in combination with the reverse vaccinology approach 
[174]. 
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Recent advances in genomics and reverse vaccinology have identified promising protein 
targets for vaccines. In many cases, suitable candidate antigens for Gram-negative bacterial 
vaccines are outer membrane proteins and these pose particular challenges in their expression 
and purification and in serotype variability. GMMA particles could be an ideal delivery 
system, especially for bacterial vaccines for developing countries, and also could encompass 
multiple antigens.  
We believe that, GMMA technology is an innovative, efficient and cost effective platform for 
vaccine manufacturing against Gram-negative bacteria moreover this platform is very flexible 
and it could be exploited applying different approaches, as immunogenic molecules source or 
as vaccines itself.  
Using genetic manipulation, it is possible increase GMMA yield, remove immunodominant 
structures, overexpress specific antigens and reduce the endotoxic activity thus GMMA could 
be potentially used as a safe and effective low cost vaccine 
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